Teligent (TLGTQ) 10-Q 27 May 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2020	May 15, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	001-08568
Entity Registrant Name	Teligent, Inc.
Entity Central Index Key	0000352998
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	01-0355758
Entity Address, Address Line One	105 Lincoln Avenue
Entity Address, City or Town	Buena
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08310
City Area Code	856
Local Phone Number	697-1441
Title of 12(b) Security	Common Stock, Par Value $0.01 Per Share
Trading Symbol	TLGT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		53,899,495

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 11,028	$ 15,508
Restricted cash	206	206
Accounts receivable, net of allowance for doubtful accounts of $2,293 and $2,208, as of March 31, 2020 and December 31, 2019, respectively	8,497	20,374
Inventories	29,542	23,031
Prepaid expenses and other receivables	2,599	2,525
Total current assets	51,872	61,644
Property, plant and equipment, net	96,422	96,349
Intangible assets, net	34,699	44,645
Goodwill	454	491
Other assets	3,499	3,776
Total assets	186,946	206,905
Current liabilities:
Accounts payable	7,274	6,875
Accrued expenses	10,394	9,285
Capital lease obligation, current	451	446
Total current liabilities	18,119	16,606
Long-term Line of Credit	25,000	25,000
Secured Long-term Debt, Noncurrent	88,997	86,452
Derivative liabilities	8,034	6,776
Deferred tax liability	185	205
Other long term liabilities	2,107	2,256
Liabilities, Total	218,792	212,212
Commitments and Contingencies
Stockholders’ deficit:
Common Stock, Value, Issued	558	558
Additional paid-in capital	118,463	117,967
Accumulated deficit	(148,310)	(121,474)
Accumulated other comprehensive loss	(2,557)	(2,358)
Total stockholders’ deficit	(31,846)	(5,307)
Total liabilities and stockholders' deficit	186,946	206,905
Senior Notes, due May 2023
Current liabilities:
Convertible Notes	53,900	53,093
Series B Senior Unsecured Convertible Notes
Current liabilities:
Convertible Notes	$ 22,450	$ 21,824

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Allowance for doubtful accounts	$ 2,293,000	$ 2,208,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	53,899,495	53,850,427
Common stock, shares outstanding (in shares)	53,899,495	53,850,427
Convertible Notes Payable
Face amount of the Notes	$ 216,341,000	$ 213,959,000
Senior Notes, due May 2023 | Convertible Notes Payable
Stated interest rate	4.75%
Face amount of the Notes	$ 66,090,000	66,090,000
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable
Face amount of the Notes	34,405,000	34,405,000
Senior Notes, due February 2023 | Convertible Notes Payable
Face amount of the Notes	90,846,000	88,464,000
Revolving Credit Facility | Line of Credit
Face amount of the Notes	$ 25,000,000	$ 25,000,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Revenue, net	$ 7,447	$ 13,122
Costs and expenses:
Cost of revenues	8,610	7,360
Selling, general and administrative expenses	6,717	5,513
Impairment charges	8,373	0
Product development and research expenses	1,800	2,989
Total costs and expenses	25,500	15,862
Operating loss	(18,053)	(2,740)
Other Expense:
Foreign currency exchange loss	(1,597)	(844)
Debt partial extinguishment of 2019 Notes	0	(185)
Interest and other expense, net	(5,876)	(4,947)
Change in the fair value of derivative liabilities	(1,258)	0
Loss before income tax expense	(26,784)	(8,716)
Income tax expense	52	8
Net loss attributable to common shareholders	$ (26,836)	$ (8,724)
Basic and diluted loss per share (in dollars per share)	$ (0.50)	$ (0.16)
Weighted average shares of common stock outstanding:
Basic and diluted shares (in shares)	53,879,333	53,805,983

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (26,836)	$ (8,724)
Other comprehensive income, net of tax:
Foreign currency translation adjustment	(199)	147
Other comprehensive income loss	(199)	147
Comprehensive loss	$ (27,035)	$ (8,577)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - 3 months ended Mar. 31, 2020 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Balance at Dec. 31, 2019	$ (5,307)	$ 558	$ 117,967	$ (121,474)	$ (2,358)
Balance (in shares) at Dec. 31, 2019		53,850,427
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation expense	496		496
Issuance of stock for vested restricted stock units		$ 0
Issuance of stock for vested restricted stock units (in shares)		49,068
Cumulative translation adjustment	(199)				(199)
Net loss	(26,836)			(26,836)
Balance at Mar. 31, 2020	$ (31,846)	$ 558	$ 118,463	$ (148,310)	$ (2,557)
Balance (in shares) at Mar. 31, 2020		53,899,495

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (26,836)	$ (8,724)
Reconciliation of net loss to net cash (used in) provided by operating activities:
Depreciation of fixed assets and leases	985	876
Provision for bad debt	85	(105)
Provision for write down of inventory	1,394	453
Stock based compensation	491	368
Amortization of debt costs and debt discount	1,704	1,523
Amortization of intangible assets	741	756
Non cash lease expense	103	97
Foreign currency exchange loss	1,597	844
Debt partial extinguishment	0	185
Loss on impairment of intangible assets	8,373	0
Non cash interest expense	1,984	2,020
Change in the fair value of derivative liabilities	1,258	0
Changes in operating assets and liabilities:
Accounts receivable	11,637	892
Inventories	(8,186)	(5,063)
Prepaid expenses, other current receivables and assets	(58)	558
Accounts payable and accrued expenses	1,889	(95)
Operating liabilities	(107)	(85)
Deferred income	0	(551)
Net cash used in operating activities	(2,946)	(6,051)
Cash flows from investing activities:
Capital expenditures	(880)	(2,129)
Net cash used in investing activities	(880)	(2,129)
Cash flows from financing activities:
Proceeds from Revolver	0	5,000
Debt issuance costs	0	(109)
Repurchase of 3.75% senior notes	0	(2,686)
Principal paid on lease obligation	(3)	(3)
Net cash (used in) provided by financing activities	(3)	2,202
Effect of exchange rate on cash and cash equivalents	(651)	(16)
Net decrease in cash, cash equivalents and restricted cash	(4,480)	(5,994)
Cash, cash equivalents and restricted cash at beginning of period	16,182	13,069
Cash, cash equivalents and restricted cash at end of period	11,702	7,075
Supplemental Cash flow information:
Cash payments for interest	388	278
Cash payments for income taxes	34	20
Non-cash operating, investing and financing transactions:
Acquisition of capital expenditures in accounts payable and accrued expenses	183	1,365
Capitalized stock compensation in capital expenditures	$ 5	$ 10

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	Mar. 31, 2020
3.75% Senior Note | Senior Notes
Stated interest rate	3.75%

Nature of the Business and Liqu

Nature of the Business and Liquidity	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Liquidity	Nature of the Business and Going Concern Nature of the Business Teligent, Inc. and its subsidiaries (collectively the “Company”) is a specialty generic pharmaceutical company. Teligent’s mission is to become a leader in the specialty generic pharmaceutical market in alternate dosage forms. Under its own label, the Company markets and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. In the United States, the Company currently markets thirty-eight generic topical pharmaceutical products and four branded generic pharmaceutical products. In Canada, the Company sells thirty-two generic and branded generic injectable products and medical devices. Generic pharmaceutical products are bioequivalent to their brand name counterparts. The Company also provides contract manufacturing services to the pharmaceutical, over the counter (“OTC”) and cosmetic markets. The Company operates its business under one segment. Its common stock is traded on the Nasdaq Global Select Market under the trading symbol “TLGT.” The Company’s principal executive office, laboratories, and manufacturing facilities are located at 105 Lincoln Avenue, Buena, New Jersey. It has additional offices located in Iselin, New Jersey, Mississauga, Canada, and Tallinn, Estonia. Impact Related to COVID-19 Pandemic In March 2020, the World Health Organization declared the outbreak of novel coronavirus disease (“COVID-19”) as a pandemic, and the Company expects its operations in all locations to be affected as the virus continues to proliferate. In alignment with the directives in the state of New Jersey, as a Pharmaceutical manufacturing facility, Teligent is considered "essential" and the Company has remained open for its business. The Company will stay open as long as permitted and conditions remain safe for its employees to continue to supply its products to the patients that need them. Teligent’s first priority is the health and safety of its employees while positioning its business to manage throughout this Pandemic. The outbreak and any preventative or protective actions that Teligent, its customers, suppliers or other third parties with which it has business relationships, or governments may take in respect of the COVID-19 outbreak could disrupt its business and the business of its customers. Global health concerns, such as COVID-19, could also result in social, economic, and labor instability in the countries in which the Company or the third parties with whom it engages operate. In addition, the COVID-19 outbreak could result in a severe economic downturn and has already significantly affected the financial markets of many countries. A severe or prolonged economic downturn or political disruption could result in a variety of risks to its business, including its ability to raise capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain its suppliers or third party CMOs, possibly resulting in supply disruption, or cause its customers to delay purchases or payments for its products. The COVID-19 pandemic may also create delays in the review and approval of its regulatory submissions as well as its pending reinspection related to the Company's warning letter and pre-approval inspection for commercial production on the newly installed injectable line at the Company’s New Jersey facility by the FDA. Given these uncertainties, the Company is unable to predict the overall impact that the COVID-19 pandemic will have on its business as of the date of this filing. During the first quarter of 2020, the Company has taken preventative measures to help ensure business continuity while maintaining safe and stable operations. It has directed all non-production employees to work from home in accordance with state and local guidelines and has implemented social distancing measures on-site at its manufacturing facility to protect employees and its products. Its employees are provided daily personal protective equipment upon their arrival to the facility and the Company has implemented temperature monitoring services at its newly established single point of entrance. The Company has also implemented a bi-weekly sanitization process of the facility. It has adjusted its production schedule to concentrate on high demand or low stock product to help reduce employee concentrations while continuing to focus on our customer demand. Under the provisions of ASC 360-10-55, the Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. The current financial results and anticipated future results of the Company have been negatively impacted due to COVID-19 and therefore the Company performed an impairment analysis for the quarter ended March 31, 2020, by comparing the expected future cash flows of the assets to the carrying value of the related intangible assets. As a result, the Company recorded an impairment charge of $8.4 million in the current quarter related to trademarks and technology of $4.9 million and product acquisition costs of $3.5 million (Note 9). The Company initiated a company-wide cost reduction initiative targeted at eliminating discretionary spending and ensuring that remaining expenditures are reduced in line with the lower demand for our products in light of COVID-19 impact to the business. The Company's Executive Leadership Team and all employees with annual salaries exceeding $100,000 accepted a 20% and 15% eight-week reduction in pay, respectively, beginning May 4, 2020. Over the same eight-week period, the Company furloughed a portion of employees at its Buena, NJ manufacturing facility. On May 15, 2020 the Company received $3.3 million of proceeds from the U.S. Small Business Administration Paycheck Protection Program (PPP) in May which is intended to help businesses keep their workforce employed during the COVID-19 crisis. The Company plans to balance the employee-related actions previously taken with the needs of the business to ensure a portion of the loan will be forgiven From late March to the end of April 2020, several data sources suggested that patient visits to the dermatologist in the United States were down more than 50% in comparison to the typical number of dermatologist visits realized prior to shelter-in-place guidelines. These percentages vary by state. In May, as some states began to relax shelter-in-place guidelines there are signs that suggest patients are beginning to return to the dermatologist and demand for the Company’s US topical products will follow. Given the level of uncertainty and potential consequences of less stringent guidelines, it is still extremely challenging to predict the pace of the anticipated ramp and whether or not there might be a second wave of decline. Going Concern ASU 205-40 – Presentation of Financial Statements – Going Concern requires management to evaluate an entity’s ability to continue as a going concern within one year after the date the financial statements are available for issuance. Specifically, management is required to evaluate whether the presence of negative conditions or events, when considered individually and in the aggregate, raise substantial doubt about an entity’s ability to continue as a going concern. Substantial doubt exists when it is probable that the entity will be unable to meet its obligations as they become due within one year after the date the financial statements are available for issuance. Management has identified the following negative conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern as of March 31, 2020: • The Company has incurred significant losses and generated negative cash flows from operations in recent years and expects to continue to incur losses and generate negative cash flow for the foreseeable future. As a result, the Company had an accumulated deficit of $148.3 million, total principal amount of outstanding borrowings of $190.3 million, and limited capital resources to fund ongoing operations at March 31, 2020. These capital resources were comprised of cash and equivalents of $11.7 million at March 31, 2020 and the generation of cash inflows from working capital. The Company’s available capital resources may not be sufficient for it to continue to meet its obligations as they become due over the next twelve months if the Company cannot improve its operating results or increase its operating cash inflows. In the event these capital resources are not sufficient, the Company may need to raise additional capital through the sale of equity or debt securities, enter into strategic business collaboration agreements with other companies, seek other funding facilities, or sell assets. However, the Company cannot provide assurances that additional capital will be available on acceptable terms or at all. Moreover, if the Company is unable to meet its obligations when they become due over the next twelve months through its available capital resources, or obtain new sources of capital when needed, the Company may have to delay expenditures, reduce the scope of its manufacturing operations, reduce or eliminate one or more of its development programs, make significant changes to its operating plan or cease its operations. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. • As disclosed in Note 7, the Company is subject to certain financial covenants as set forth in the April 6, 2020 amendments to the Senior Credit Facilities. These financial covenants include a trailing twelve months (“TTM”) Minimum Revenue covenant that is required to be met each quarterly period from March 31, 2020 through December 31, 2020, a TTM Minimum Adjusted EBITDA that is required to be met each quarterly period from March 31, 2021 through maturity, and a minimum liquidity covenant tested at all times through the term of the agreement. These amendments supersede the financial covenants included in the original and amended agreements disclosed in Note 7. In the event the Company is unable to comply with these covenants, or obtain a waiver from its lenders, the lender shall have the right, but not the obligation, to permanently reduce the commitment in whole or in part or to declare all or any portion of the outstanding balance due and payable. Furthermore, in the event that outstanding balances under the Ares Credit agreements are declared due and payable by the lender, the lenders of the 2023 Series A and Series B Unsecured Convertible Notes shall have the right, but not the obligation, to declare all of the outstanding balance due and payable as well. If the Company is unable to raise additional capital to meet these obligations, the Company may have to seek other strategic alternatives, including ceasing its operations. The accompanying financial statements do not include any adjustments that might result from the outcome of these uncertainties. • The Company was in compliance with its financial covenants as of March 31, 2020. However, as a result of the impacts of the COVID-19 pandemic, the Company expects to be unable to continue to comply with the trailing twelve months revenue covenant throughout 2020. If it fails to comply with its trailing twelve months revenue covenant, an event of default under the Credit Agreements would be triggered and its obligations under the Senior Credit Facilities (defined in Note 7) or other agreements (including as a result of cross-default provisions) may be accelerated. During the first quarter of 2020, the Company recorded a $5.3 million derivative liability associated with certain mandatory prepayment penalties and the recognition of future interest payments in the anticipation of a potential future default on its Senior Credit Facilities (Note 8).

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair presentation of the results for the interim periods of the fiscal years ending December 31, 2020 and 2019. Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the accompanying unaudited condensed consolidated financial statements should be read in conjunction with the notes to the audited consolidated financial statements contained in the Company’s Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on April 13, 2020. Principles of Consolidation The condensed consolidated financial statements include the accounts of Teligent, Inc. and its wholly owned and majority-owned subsidiaries. The Company consolidated the following entities: Igen, Inc., Teligent Pharma. Inc., Teligent Luxembourg S.à.r.l., Teligent OÜ, and Teligent Canada Inc., in addition to the following inactive entities: Microburst Energy, Inc., Blood Cells, Inc. and Flavorsome, Ltd. All inter-company accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the valuation of derivative liabilities associated with certain Notes and the Senior Credit Facility, sales returns and allowances, allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related valuation allowances, stock based compensation, the assessment for the impairment of long-lived assets (including intangibles, goodwill and property, plant and equipment), property, plant and equipment and legal accruals for environmental cleanup and remediation costs. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Cash Equivalents The Company considers all highly liquid instruments purchased with the original maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. Cash and cash equivalents include cash on hand and bank demand deposits used in the Company’s cash management program. The Company has restricted cash, consisting of escrow accounts and letter of credits, which are included within other long-term assets on the Condensed Consolidated Balance Sheet. Pursuant to the New Credit Facilities agreement, proceeds from the 2023 Term Loan were deposited in a blocked bank account and restricted for use for the sole purpose of repurchasing the outstanding 2019 Notes. In the beginning of 2019, the Company used a total of $2.7 million of the restricted cash to repurchase a portion of the remaining 2019 Notes. The Company settled the remaining 2019 Notes upon its maturity in December 2019 (Note 7). The following table provides a reconciliation of cash and cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheet to the total amounts in the Condensed Consolidated Statement of Cash Flows as follows: March 31, 2020 March 31, 2019 Cash and cash equivalents $ 11,028 $ 6,397 Restricted cash 206 206 Restricted cash in other assets 468 472 Cash, cash equivalents and restricted cash in the statement of cash flows $ 11,702 $ 7,075 Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, trade receivables, restricted cash, accounts payable and other accrued liabilities at March 31, 2020 approximate their fair value for all periods presented. The Company measures fair value in accordance with ASC 820-10, “Fair Value Measurements and Disclosures”. ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820-10 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. As of March 31, 2020, the fair value of the Company's 2023 Series A Notes was approximately $24.8 million compared to the carrying value of $53.9 million and the fair value of the Company's 2023 Series B Notes was $22.1 million including the derivative liability of $2.8 million as mentioned below. As of March 31, 2020, based on level 3 inputs, the fair value of the derivative liability associated with the Company's 2023 Series B Notes was $2.8 million and the fair value of the Company's derivative liability associated with certain mandatory prepayment penalties and the recognition of future interest payments in the anticipation of a potential future default on its Senior Credit Facilities was $5.3 million which the Company recorded in the first quarter of 2020 (Note 8). Loss Per Common Share Basic loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted loss per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Potential dilutive common stock equivalents include shares issuable upon the conversion of the notes and the exercise of options and warrants. For the three months ended March 31, 2020, the potential dilutive common stock equivalents have been excluded from the computation of diluted loss per share, as their effect would have been anti-dilutive. (in thousands except shares and per share data) Three months ended March 31, 2020 2019 Basic loss per share computation: Net loss - basic and diluted $ (26,836) $ (8,724) Weighted average common shares - basic and diluted 53,879,333 53,805,983 Basic and diluted loss per share $ (0.50) $ (0.16) Concentration of Credit Risk Major customers of the Company are defined as those constituting greater than 10% of the Company's total revenue. For the three months ended March 31, 2020, one of the Company’s customers accounted for 16.9% of the Company’s revenue. For the three months ended March 31, 2019, two of the Company’s customers accounted for 48% of the Company’s revenue, consisting of 30% and 18%, respectively. Accounts receivable related to the Company’s major customers comprised 12% of all accounts receivable as of March 31, 2020 and 37% as of March 31, 2019 respectively. The loss of one or more of these major customers could have a significant impact on our revenues and harm our business and results of operations. For the three months ended March 31, 2020, domestic net revenues were $5.6 million and foreign net revenues were $1.8 million. As of March 31, 2020, domestic assets were $146.4 million and foreign assets were $40.5 million. For the three months ended March 31, 2019, domestic net revenues were $9.7 million and foreign net revenues were $3.4 million. As of March 31, 2019, domestic assets were $135.5 million and foreign assets were $56.4 million. Recently Issued Not Yet Adopted Accounting Pronouncements In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU No. 2020-04”). The update provides optional guidance for a limited period to ease the potential burden in accounting for (or recognizing the effects of) contract modifications on financial reporting caused by reference rate reform. ASU 2020-04 is effective for all entities as of March 12, 2020 through December 31, 2022. The Company is evaluating the impact upon adoption of the update on its Condensed Consolidated Financial Statements and related disclosures. In December 2019, the FASB issued an accounting standard update to simplify the accounting for income taxes. The standard’s amendments include changes in various subtopics of accounting for income taxes including, but not limited to, accounting for “hybrid” tax regimes, tax basis step-up in goodwill obtained in a transaction that is not a business combination, intraperiod tax allocation exception to an incremental approach, ownership changes in investments, interim-period accounting for enacted changes in tax law, and year-to-date loss limitation in interim-period tax accounting. The guidance is effective for fiscal years beginning after December 15, 2020 with early adoption permitted, including the interim periods within those years. The Company is evaluating the impact this guidance will have on the Company’s Condensed Consolidated Financial Statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU No. 2016-13”), which requires that a financial asset (or a group of financial assets) measured at an amortized cost basis be presented at the net amount expected to be collected. This approach to estimating credit losses applies to most financial assets measured at amortized cost and certain other instruments, including but not limited to, trade and other receivables. The amendments in this update are initially effective for public business entities for fiscal years beginning after December 15, 2019. The Financial Accounting Standards Board subsequently postponed the effective date for small reporting companies to January 2023, which for the Company means January 1, 2023. Based on the current status of the evaluation, the Company believes the adoption of the guidance will not have a material impact on its Condensed Consolidated Financial Statements and related disclosures. The Company expects to continue and finalize its evaluation and assessment as required by the guidance upon adoption.

Revenues, Recognition and Allow

Revenues, Recognition and Allowances	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenues, Recognition and Allowances	Revenues, Recognition and Allowances Revenue Recognition The Company derives its revenues from three types of transactions: sales of its own pharmaceutical products (Company product sales), sales of the manufactured products for its customers (contract manufacturing sales), and research and product development services performed for third parties. Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience as well as applicable information currently available. Company Product Sales Revenue from Company product sales is recognized upon transfer of control of a product to a customer at a point in time, generally as the Company's products are sold on a FOB destination basis and because of the inventory risk and risk of ownership pass to the customer upon delivery. Company product sales are recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. Contract Manufacturing Sales The Company recognizes revenue for contract manufacturing sales over-time, as milestones are achieved. Shipments are made in accordance with sales commitments and related sales orders that the Company entered into with customers either verbally or in written form. Contract manufacturing sales are recognized net of accruals for cash discounts which are established at the time of sale and are included in Revenue, net in the Company's Condensed Consolidated Statement of Operations. Research and Development Services and Other Income The Company establishes agreed-upon product development agreements with its customers to perform product development services. Revenues are recognized in accordance with the agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Other types of revenue include royalty or licensing revenue that would be recognized over time, at a point in time, or based upon the contractual term upon completion of the earnings process. Judgments are required to evaluate contingencies such as potential variances in the schedule or costs, the impact of change orders, liability claims, contract disputes, or the achievement of contractual performance standards. Revenues by Transaction Type The Company operates under one reportable segment and therefore the results of the Company's operations are reported on a consolidated basis, which is consistent with internal management reporting utilized by the chief decision maker. Net revenues for the three months ended March 31, 2020 and 2019 were as follows: Three months ended March 31, 2020 2019 Company product sales $ 7,139 $ 12,495 Contract manufacturing sales 197 542 Research and development services and other income $ 111 $ 85 Revenue, net $ 7,447 $ 13,122 Disaggregated information for the Company product sales revenue has been recognized in the accompanying unaudited interim Condensed Consolidated Statements of Operations and is presented below according to contract type: Three months ended March 31, Company Product Sales 2020 2019 Topical $ 5,380 $ 9,032 Injectables 1,759 3,463 Total $ 7,139 $ 12,495 In the three months ended March 31, 2020, the Company did not incur, and therefore did not defer, any material incremental costs to obtain contracts. Sales Returns and Allowances As is customary in the pharmaceutical industry, the Company’s product sales are subject to a variety of deductions, including chargebacks, rebates, cash discounts, other allowances, and returns. Product sales are recorded net of accruals for returns and allowances, which are established at the time of sale. The Company analyzes the adequacy of its accruals for returns and allowances quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. These provisions are estimates based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The Company uses a variety of methods to assess the adequacy of its returns and allowances reserves to ensure that its financial statements are fairly stated. These include periodic reviews of customer inventory data, customer contract programs, subsequent actual payment experience, and product pricing trends to analyze and validate the return and allowances reserves. Net revenue and accounts receivable balances in the Company’s condensed consolidated financial statements are presented net of sales, returns, and allowances (SRA). Accounts receivable are presented net of SRA estimates of $23.4 million and $30.5 million at March 31, 2020 and December 31, 2019, respectively. Certain SRA balances are included in accounts payable and accrued expenses. The allowance for doubtful accounts was $2.3 million and $2.2 million at March 31, 2020 and December 31, 2019, respectively. The allowance for doubtful accounts was primarily related to one specific customer for $1.7 million. Chargebacks are one of the Company's most significant estimates for recognition of product sales. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by its wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve vary with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks estimates the expected wholesaler sell-through levels to indirect customers at contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from its largest wholesale customers. This customer inventory information is used to establish the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent the majority of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated. Rebates are used for various discounts which can be programs or one-time events. The Company reviews the percentage of products sold through these programs by reviewing chargeback data and uses the appropriate percentages to calculate the rebate accrual. Rebates are invoiced monthly, quarterly, or annually and reviewed against the accruals. Other items that could be included in accrued rebates would be price protection fees, shelf stock adjustments (SSAs), or other various amounts that would serve as one-time discounts on specific products. The Company's adjustments for the deductions to gross product sales are as follows: Three months ended March 31, 2020 2019 Gross product sales $ 23,166 $ 27,414 Deduction to gross product sales: Chargebacks and billbacks 11,955 10,886 Wholesaler fees for service 1,142 1,766 Sales discounts and other allowances 2,930 2,267 Total reduction to gross product sales $ 16,027 $ 14,919 Company product sales, net $ 7,139 $ 12,495 Financing and Payment The Company's payment terms vary by the type of the customer and the products or services offered. The term between invoicing and when payment is due is not significant. Generally, the Company does not incur incremental costs to obtain contracts. The Company does not adjust revenue for the effects of a significant financing component as the Company's customers generally pay within 100 days. Costs to Obtain or Fulfill a Customer Contract Costs related to shipping and handling are comprised of outbound freight and associated labor. The Company accounts for shipping and handling activities related to contracts with customers as fulfillment costs which are included in the cost of sales in the Condensed Consolidated Statements of Operations.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are valued at the lower of cost or net realizable value and using the first-in-first-out method. Inventories as of March 31, 2020 and December 31, 2019 consisted of: March 31, 2020 December 31, 2019 Raw materials $ 15,221 $ 14,117 Work in progress 217 133 Finished goods 17,704 10,989 Inventories reserve (3,600) (2,208) Inventories, net $ 29,542 $ 23,031

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment consists of the following: March 31, 2020 December 31, 2019 Land $ 401 $ 401 Building and improvements 58,969 58,959 Machinery and equipment 14,961 14,897 Computer hardware and software 4,814 4,771 Furniture and fixtures 702 705 Construction in progress 31,694 30,759 111,541 110,492 Less accumulated depreciation and amortization (15,119) (14,143) Property, plant and equipment, net $ 96,422 $ 96,349 The Company recorded depreciation expense of $1.0 million and $0.9 million for the three months ended March 31, 2020 and 2019, respectively.

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	Leases According to ASC Topic 842, Leases , the Company recognizes Right-of-Use ("ROU") assets and lease liabilities for all leases with terms greater than 12 months. The Company determines whether an agreement is a lease at its inception. The Company has operating and finance leases for its corporate, manufacturing, and international facilities as well as certain equipment. Its leases have remaining terms of less than one nine The discount rates utilized ranged from 4.86% to 8.60% and were utilized to determine the present value of the lease liabilities. The components of lease expense were as follows: Three months ended Three months ended Operating lease cost $ 158 $ 159 Finance lease cost: Amortization of right-of-use assets 4 3 Interest on lease liabilities 1 2 Total finance lease cost $ 5 $ 5 Right-of-use assets obtained in exchange for new operating lease liabilities was zero and $1.0 million as of March 31, 2020 and 2019, respectively. Cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2020 and 2019 was $0.1 million and $0.1 million, respectively. Cash paid for amounts included in the measurement of finance lease liabilities for the three months ended March 31, 2020 and 2019, respectively, was not material. Supplemental balance sheet information related to leases as of the periods presented were as follows: March 31, 2020 December 31, 2019 Operating Leases Other assets $ 2,321 $ 2,453 Other current liabilities 438 434 Other long-term liabilities 2,053 2,199 Total operating lease liabilities 2,491 2,633 Finance Leases Property, plant, and equipment 81 81 Accumulated depreciation (18) (12) Property, plant, and equipment, net 63 69 Other current liabilities 13 12 Other long-term liabilities 54 57 Total finance lease liabilities $ 67 $ 69 The weighted average remaining lease terms as of March 31, 2020 for operating and financing leases were 6.1 years and 4.4 years, respectively. The weighted average discount rates for operating and finance leases as of March 31, 2020 were 8.3% and 8.0%, respectively. As of March 31, 2020, maturities of lease liabilities were as follows: Operating Financing Year Ending December 31, Leases Leases Remainder of 2020 $ 466 $ 14 2021 602 18 2022 546 18 2023 545 18 2024 232 12 2025 204 — Thereafter 622 — Total lease payments 3,217 80 Less imputed interest 726 13 Total $ 2,491 $ 67
Leases	Leases According to ASC Topic 842, Leases , the Company recognizes Right-of-Use ("ROU") assets and lease liabilities for all leases with terms greater than 12 months. The Company determines whether an agreement is a lease at its inception. The Company has operating and finance leases for its corporate, manufacturing, and international facilities as well as certain equipment. Its leases have remaining terms of less than one nine The discount rates utilized ranged from 4.86% to 8.60% and were utilized to determine the present value of the lease liabilities. The components of lease expense were as follows: Three months ended Three months ended Operating lease cost $ 158 $ 159 Finance lease cost: Amortization of right-of-use assets 4 3 Interest on lease liabilities 1 2 Total finance lease cost $ 5 $ 5 Right-of-use assets obtained in exchange for new operating lease liabilities was zero and $1.0 million as of March 31, 2020 and 2019, respectively. Cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2020 and 2019 was $0.1 million and $0.1 million, respectively. Cash paid for amounts included in the measurement of finance lease liabilities for the three months ended March 31, 2020 and 2019, respectively, was not material. Supplemental balance sheet information related to leases as of the periods presented were as follows: March 31, 2020 December 31, 2019 Operating Leases Other assets $ 2,321 $ 2,453 Other current liabilities 438 434 Other long-term liabilities 2,053 2,199 Total operating lease liabilities 2,491 2,633 Finance Leases Property, plant, and equipment 81 81 Accumulated depreciation (18) (12) Property, plant, and equipment, net 63 69 Other current liabilities 13 12 Other long-term liabilities 54 57 Total finance lease liabilities $ 67 $ 69 The weighted average remaining lease terms as of March 31, 2020 for operating and financing leases were 6.1 years and 4.4 years, respectively. The weighted average discount rates for operating and finance leases as of March 31, 2020 were 8.3% and 8.0%, respectively. As of March 31, 2020, maturities of lease liabilities were as follows: Operating Financing Year Ending December 31, Leases Leases Remainder of 2020 $ 466 $ 14 2021 602 18 2022 546 18 2023 545 18 2024 232 12 2025 204 — Thereafter 622 — Total lease payments 3,217 80 Less imputed interest 726 13 Total $ 2,491 $ 67

Debt

Debt	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Debt	Debt Convertible Notes 2019 Notes, 2023 Notes and 2023 Series B Notes On December 16, 2014, the Company issued $125.0 million aggregate principal amount of Convertible 3.75% Senior Notes, due 2019 (the “2019 Notes”). On December 22, 2014, the Company announced the closing of the initial purchasers’ exercise in full of their option to purchase an additional $18.75 million aggregate principal amount of 2019 Notes. The 2019 Notes bore interest at a fixed rate of 3.75% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2015, and matured on December 15, 2019, unless earlier repurchased, redeemed or converted. The 2019 Notes were convertible into shares of the Company’s common stock, cash or a combination thereof. On May 20, 2015, the Company received shareholder approval for the increase in the number of shares of common stock authorized and available for issuance upon possible conversion of the 2019 Notes. On April 27, 2018, the Company entered into separate exchange agreements with certain holders of the 2019 Notes. The agreements gave the holders the right to exchange, in aggregate, $75.1 million of the 2019 Notes for $75.1 million of new Convertible 4.75% Senior Notes due 2023 (the “2023 Notes”). The 2023 Notes bear a fixed interest rate of 4.75% per year, payable semi-annually with the principal payable in May 2023. At the option of the holders, the 2023 Notes are convertible into shares of the Company’s common stock, cash or a combination thereof. The initial conversion rate is $4.45 per share, subject to certain adjustments, related to either the Company's stock price volatility, or the Company's declaration of a stock dividend, stock distribution, share combination or share split expected dividends or other anti-dilutive activities. In addition, holders will be entitled to receive additional shares of common stock for a potential increase of the conversion rate up to $280.90 per share under a make-whole provision in some circumstances. The Company incurred debt issuance costs of $1.6 million upon issuance of the 2023 Notes. In accordance with accounting for convertible debt within the cash conversion guidance of ASC 470-20, the Company allocated the principal amount of the 2023 Notes between its liability and equity components. The carrying amount of the liability component was determined by measuring the fair value of a similar debt instrument of similar credit quality and maturity that did not have the conversion feature. The carrying amount of the equity component, representing the embedded conversion option, was determined by deducting the fair value of the liability component from the principal amount of the 2023 Notes as a whole. The equity component was recorded to additional paid-in capital and is not remeasured as long as it continues to meet the conditions for equity classification. The excess of the principal amount of the 2023 Notes over the carrying amount of the liability component was recorded as a debt discount of $19.0 million and is being amortized to interest expense using the effective interest method through the maturity date. The Company allocated the total amount of debt issuance costs incurred to the liability and equity components using the same proportions as the proceeds from the 2023 Notes. The debt issuance costs attributable to the liability component were recorded as a direct deduction from the liability component of the 2023 Notes and are being amortized to interest expense using the effective interest method through the maturity date. Transaction costs attributable to the equity component were netted with the equity component of the 2023 Notes in additional paid-in capital. The effective interest rate of the 2023 Notes, inclusive of the debt discount and issuance costs, is 11.90%. The exchange of $75.1 million of the 2019 Notes for the 2023 Notes is considered a debt extinguishment under ASC 470-50. The 2019 Notes are accounted for under cash conversion guidance ASC 470-20, which requires the Company to allocate the fair value of the consideration transferred upon settlement to the extinguishment of the liability component and the reacquisition of the equity component upon derecognition. In accordance with the aforementioned guidance, the Company allocated a portion of the $75.1 million to the extinguishment of the liability component equal to the fair value of that component immediately before extinguishment and recognized a $2.5 million extinguishment loss in the Condensed Consolidated Statement of Operations to measure the difference between (i) the fair value of the liability component and (ii) the net carrying amount of the liability component (which is already net of any unamortized debt issuance costs). In addition, the Company recorded a $7.6 million reduction of Additional Paid in Capital in connection with the extinguishment of $75.1 million of the 2019 Notes. In December 2018 the Company used $52.8 million of proceeds from the Senior Credit Facilities (see below) to repurchase a portion of the 2019 Notes as well as $0.3 million of proceeds to pay for transaction costs. The repurchase of the 2019 Notes is considered a debt extinguishment under ASC 470-50. The 2019 Notes are accounted for under cash conversion guidance ASC 470-20, which requires the Company to allocate the fair value of the consideration transferred upon settlement to the extinguishment of the liability component and the reacquisition of the equity component upon derecognition. In accordance with the guidance above, the Company allocated a portion of the $52.8 million to the extinguishment of the liability component equal to the fair value of that component immediately before extinguishment and recognized a $1.7 million extinguishment loss in the Consolidated Statement of Operations to measure the difference between (i) the fair value of the liability component and (ii) the net carrying value amount of the liability component (which is already net of any unamortized debt issuance costs). In addition, the Company recorded a $2.9 million reduction of Additional Paid in Capital in connection with the extinguishment of the 2019 Notes. In the beginning of 2019, the Company used a total of $2.7 million of proceeds from the Senior Credit Facilities to repurchase a portion of the remaining 2019 Notes. The repurchase of the 2019 Notes is considered a debt extinguishment under ASC 470-50. The 2019 Notes are accounted for under cash conversion guidance ASC 470-20, which requires the Company to allocate the fair value of the consideration transferred upon settlement to the extinguishment of the liability component and the reacquisition of the equity component upon derecognition. In accordance with the guidance above, the Company allocated a portion of the $2.7 million to the extinguishment of the liability component equal to the fair value of that component immediately before extinguishment and recognized a $0.2 million extinguishment loss in the Consolidated Statement of Operations to measure the difference between (i) the fair value of the liability component and (ii) the net carrying value amount of the liability component (which is already net of any unamortized debt issuance costs). The reduction of Additional Paid in Capital in connection with this extinguishment was immaterial. The Company settled the remaining 2019 Notes of $13.0 million in principal upon its maturity in December 2019. 2023 Series B Notes On October 31, 2019, the Company closed its offering of the 2023 Series B Notes in the aggregate principal amount of $34.4 million (“2023 Series B Notes” and together with the 2023 Notes, the “Notes”). The 2023 Series B Notes will mature in May 2023 and are convertible at the option of the holder at any time prior to maturity at an initial conversion price of $0.72 per share, subject to adjustment under certain circumstances. The 2023 Series B Notes and any shares of common stock issuable upon conversion of the 2023 Series B Notes (the “Conversion Shares”) have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other jurisdiction’s securities laws, and the 2023 Notes and the Conversion Shares may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. The Company does not intend to file a registration statement for the resale of the 2023 Series B Notes or any Conversion Shares. As part of the offering, the Company entered into agreements with certain holders of its existing 2023 Notes to exchange $9.0 million of the 2023 Notes for $5.1 million of the 2023 Series B Notes. The gross cash proceeds of approximately $29.3 million from the financing were used to extinguish the Company’s existing 2019 Notes in December 2019 and intended to pay amounts owing with respect to other indebtedness and to fund general corporate and working capital requirements. The 2023 Series B Notes bear interest at a rate of 7.00% per annum if paid in cash, semiannually in arrears on May 1 and November 1 of each year, beginning on May 1, 2020. The Company also has an option, and has agreed with its senior lender, to PIK the interest at 8.00% per annum, to defer cash payments. The net proceeds from the financing were $26.9 million after deducting a total of $2.3 million of the initial purchasers’ discounts and professional fees associated with the transaction. Under ASC 470-60, Troubled Debt Restructurings by Debtors, the exchange of the $9.0 million of the 2023 Notes for the $5.1 million of the 2023 Series B Notes represents a troubled debt restructuring ("TDR"). The TDR did not result in a gain recognition. As a result, a new effective interest rate was established based on the $7.2 million carrying value of the original debt, net of the $2.0 million fair value of the embedded derivative liability related to the new debt issued in the TDR and $0.2 million issuance costs, getting accreted to $6.8 million representing the total amount of the future undiscounted cash flows related to the $5.1 million of the 2023 Series B Notes. In accordance with ASC 815-15, Derivatives and hedging, Embedded Derivatives, the embedded conversion option should be bifurcated and separately accounted for as a derivative instrument, because the Company did not have enough authorized shares available to share-settle the conversion option. Such derivative instruments should be initially and subsequently measured at fair value, with changes in fair value recognized in earnings (see Note 7). The derivative liability recorded at the issuance date was $13.5 million, including the $2.0 million above accounted for in the TDR, which was subsequently remeasured to $2.8 million as of March 31, 2020, with $4.0 million recognized as a gain on change in fair value of the derivative in the Company's statement of operations mainly due to a share price decline during the first quarter of 2020. Further, the $0.9 million of allocated issuance costs associated with the bifurcated conversion features embedded in the notes was recognized as a loss on debt restructuring in the Company’s statement of operations for the year ended December 31, 2019. In accordance with ASC 470-20, the initial carrying amount of the liability component of the 2023 Series B Notes, excluding the $5.1 million portion above is accounted for as a TDR, upon issuance is the residual amount between total proceeds from the transaction and the derivative liability net of allocated issuance costs. The $1.4 million debt issuance costs attributable to the liability component were recorded as a direct deduction from the liability component of the 2023 Series B Notes and are being amortized to interest expense using the effective interest method through the maturity date. The discount from the par amount of the 2023 Series B Notes will be accreted to par utilizing the effective-interest rate method over the term of the Notes from the issuance date through May 2023. The effective interest rate of the 2023 Notes, inclusive of the debt discount and issuance costs is 27.4%. Senior Credit Facilities On December 13, 2018, the Company entered into: (i) a First Lien Revolving Credit Agreement, by and among the Company, as the borrower, certain of our subsidiaries, as guarantors, the lenders from time to time party thereto, and ACF Finco I LP, as administrative agent (the “First Lien Agent”) (as amended on October 31, 2019, the “First Lien Credit Agreement”) and (ii) a Second Lien Credit Agreement, by and among us, as the borrower, certain of our subsidiaries, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent (the “Second Lien Agent”) (as amended on February 8, 2019, June 29, 2019 and October 31, 2019, the “Second Lien Credit Agreement” and, together with the First Credit Agreement, the “Senior Credit Facilities”). The Senior Credit Facilities consist of a first lien asset based revolving credit facility of up to $25.0 million("Revolver") and an aggregate of $80.0 million in original principal amount of second lien term loans consisting of a $50.0 million initial term loan and a $30.0 million delayed draw term loan A (collectively, the “Term Loans”). The Senior Credit Facilities also included a $15.0 million delayed draw term loan B commitment, which remained undrawn and expired on October 31, 2019. As of March 31, 2020, $25.0 million was drawn under the Revolver and $90.8 million of Term Loans were outstanding. The Revolver was fully drawn in 2019. The Company extended commitments related to undrawn amounts of the Delayed Draw Term Loan A from June 30, 2019 to December 13, 2019, pursuant to an amendment the Company entered with the Second Lien Agent on July 18, 2019. The extended Delayed Draw Term Loan A was subsequently drawn down by the Company in December 2019. Drawn amounts under the Delayed Draw Term Loans mature at the same time as the Initial Term Loan. The Term Loans mature on the earliest to occur of June 23, 2024 and the date of that is 181 days prior to the maturity date of each of (x) the 2023 Notes and (y) the 2023 Series B Notes. The Revolver matures on the earliest to occur of the June 23, 2024 and the date of that is 91 days prior to the maturity date of each of (x) the 2023 Notes and (y) the 2023 Series B Notes. The Company’s ability to borrow under the Revolver is subject to a borrowing base determined based upon eligible inventory, eligible equipment, eligible real estate and eligible receivables. The Senior Credit Facilities are secured by substantially all of the Company’s assets. All of the Company’s debt is subordinated to the Senior Credit Facilities. The liens securing the Term Loans are subordinate to the liens securing the Revolver. The Senior Credit Facilities had customary financial and non-financial covenants, including affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults on other material indebtedness, as well as events of default triggered by a change of control and certain actions initiated by the FDA which were superseded by the amendments noted below. The financial covenants consisted of a minimum revenue test, a minimum adjusted EBITDA test and a maximum total net leverage ratio. The Revolver bears interest at a fluctuating rate of interest equal to one, two, three or six-month LIBOR plus a margin of 3.75% or a rate based on the prime rate plus a margin of 2.75%. The Term Loans bear interest at a fluctuating rate of interest equal to one, two, three or six-month LIBOR plus a margin of 8.75% or a rate based on the prime rate plus a margin of 7.75%. Interest on the Senior Credit Facilities is payable in cash quarterly in arrears (or more frequently in connection with customary LIBOR interest provisions), provided, that the Company may elect (and has covenanted to the lenders under its First Lien Credit Agreement to) pay interest on the Term Loans in kind until the earlier to occur of the date upon which Company has provided financial statements demonstrating twelve-months of revenue of at least $125.0 million and (ii) December 28, 2020. Amounts drawn under the Revolver may be prepaid at the option of the Company without premium or penalty, subject, in the case of acceleration of the Revolver or termination or reduction of the revolving credit commitments thereunder, to certain call protections which vary depending on the time at which such prepayments are made. Amounts drawn under the Revolver are subject to mandatory prepayment to the extent that aggregate extensions under the Revolver exceed the lesser of the revolving credit commitment then in effect and the borrowing base then in effect, and upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain insurance proceeds and condemnation awards and issuances of certain debt obligations. Amounts outstanding under the Term Loans may be prepaid at the option of the Company subject to applicable premiums, including a make-whole premium, and certain call protections which vary depending on the time at which such prepayments are made. Subject to payment of outstanding obligations under the Revolver as a result of any corresponding mandatory prepayment requirements thereunder, amounts outstanding under the Term Loans are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain insurance proceeds and condemnation awards, issuances of certain debt obligations and a change of control transaction. In connection with the Revolver the Company incurred a debt discount of $0.5 million and debt issuance issue costs of $0.3 million. The debt discount is due to annual fees and lender fees paid on the initial drawdown of $15.0 million. The debt issuance costs and debt discount are recorded as an asset on the Consolidated Balance Sheet and are amortized to interest expense using the straight-line method through the estimated Revolver maturity date. The annual fees related to the Revolver and the Initial Term Loan are amortized to interest expense using the straight-line method over the annual period they relate to. In connection with the Initial Term Loan and Delayed Draw Term Loan A, the Company incurred a debt discount of $1.8 million and debt issuance issue costs of $0.8 million. The debt discount is due to lender fees paid on the Initial Term Loan of $50.0 million and drawdown of Delayed Draw Term Loan A of $20.0 million. The debt issuance costs and debt discount costs are amortized to interest expense using the effective interest rate method through the estimated maturity date. In addition, the Company incurred $0.5 million of debt issuance costs related to the commitment fees paid to the lenders for the undrawn amounts of the Delayed Draw Term Loans. These debt issuance costs are recorded as an asset on the balance sheet and amortized on a straight-line basis over the access period of the Delayed Draw Term Loans through June 30, 2019. The effective interest rates, inclusive of the debt discounts and issuance costs, for the various borrowing tranches of the Revolver were between 6.2% and 9.1%. The effective interest rates, inclusive of the debt discounts and issuance costs for the Initial Term Loan and Delayed Draw Term Loan A were between 9.1% and 12.2%. The Initial Term Loan of $50.0 million and $15.0 million of the Revolver were drawn by the Company on December 13, 2018. On December 21, 2018, the Company drew $20.0 million of the Delayed Draw Term Loan A. In January 2019, the Company drew $5.0 million and subsequently the remaining $5.0 million under the Revolver were drawn down by the Company in April 2019. On September 18, 2019, pursuant to terms of the First Lien Credit Agreement, the Company borrowed an advance in the aggregate principal amount of $2.5 million (the “Protective Advance”). The Protective Advance is a secured Obligations under the First Lien Credit Agreement and bears interest at the rate applicable to the Revolver. The Protective Advance was subsequently repaid in November 2019 along with a repayment fee of $0.1 million. The Company drew down the remaining $10.0 million under its borrowing capacity of Delayed Draw Term Loan A before its expiry in December of 2019. The $15.0 million Delayed Draw Term Loan B expired upon the issuance of the 2023 Series B Notes, prior to the Company drawing down any monies. The Term Loans are governed by the Second Lien Credit Agreement. The Term Loans include a 24-month paid-in-kind interest option available to the Company should it choose to defer cash payments in order to maintain the liquidity needed to continue launching new products, and preparing for an FDA prior approval inspection of its new injectable manufacturing facility. The Company has elected the paid-in-kind interest option and increased the principal balance of Term Loans by $2.4 million and $10.9 million for the three months and since inception through the period ended March 31, 2020, respectively. On April 6, 2020 (the “Amendment Closing Date”), the Company entered (i) Amendment No. 2 of the Revolver and Amendment No. 4 of the Term Loans, effective as of December 31, 2019. The amendments collectively among other things, (i) increase the interest rates, (ii) reset certain prepayment premiums and modify the terms of certain mandatory prepayments and (iii) modify certain financial covenant levels inclusive of the disposition of prior covenants as of and for the period ended December 31, 2019. The Company was in compliance with its financial covenants as of March 31, 2020. However, as a result of the impacts of the COVID-19 pandemic, the Company expects to be unable to continue to comply with the trailing twelve months revenue covenant throughout 2020. If the Company fails to comply with its trailing twelve months revenue covenant, an event of default under the Credit Agreement would be triggered and its obligations under the Senior Credit Facilities or other agreements (including as a result of cross-default provisions) may be accelerated. As such, the Company recorded a $5.3 million derivative liability associated with certain mandatory prepayment penalties and the recognition of future interest payments in the anticipation of a potential future default on its Senior Credit Facilities (Note 8). The associated increase in interest rates are effective as of the Amendment Closing Date. The Revolver bears interest at a fluctuating rate of interest equal to the one, two, three or six-month LIBOR plus a margin of 5.5% or a rate based on the prime rate plus a margin of 4.5%, with a LIBOR floor of 1.5%. The Term Loans bear interest at a fluctuating rate of interest equal to the one, two, three or six-month LIBOR plus a margin of 13.0% or a rate based on the prime rate plus a margin of 12.0%, with a LIBOR floor of 1.5%. Interest on the Senior Credit Facilities is payable in cash quarterly in arrears (or more frequently in connection with customary LIBOR interest provisions), provided, that the Company may elect (and has covenanted to the lenders under its Senior Credit Facilities and subsequent amendments thereto) to pay interest on the Term Loans in kind through December 13, 2021 but only if the following occurs: (1) the Company receives a “warning letter close-out letter” from the Federal Drug Administration in response to corrective actions taken by the Company since receipt of the warning letter in November 2019 and (2) the Company receives a written recommendation from the Federal Drug Administration setting forth its approval decision in respect of the pre-approval inspection for commercial production on the newly installed injectable line at the Company’s New Jersey facility. If only one of those items occurs by December 13, 2020, then the Company may still elect to pay interest in kind during 2021, but only from the time the second condition has been satisfied until December 13, 2021. Thereafter, a portion of interest on the loans accruing at a rate of 4.25% per annum may continue to be paid in kind. Both amendments provide that in the event of receipt of net proceeds from a disposition triggering a mandatory prepayment, net proceeds of such disposition will be applied as follows: (i) first, to be retained by the Company or applied to amounts outstanding under the First Lien Credit Agreement until such time as liquidity of the Company and its subsidiaries equals $10.0 million, (ii) next to amounts outstanding under the Revolver (without a permanent reduction in the revolving loan commitments of the lenders) until such amounts are paid in full (with the first lien administrative agent having the right to waive such prepayment, in which event, such net proceeds are applied to amounts outstanding under the Second Lien Credit Agreement), and (iii) finally, to amounts outstanding under the Term Loans. In addition, pursuant to the Revolver, the Company has agreed at all times to maintain book cash of the Company and its subsidiaries not in excess of $10.0 million with any excess being required to prepay the outstanding obligations under the Revolver. The following additions and changes to financial covenants set forth in both Amendments are: (i) a new minimum net revenue covenant is added that is tested on the last day of each fiscal quarter from March 31, 2020 until the quarter ending December 31, 2020, (ii) resets a minimum consolidated adjusted EBITDA covenant that is tested on the last day of each fiscal quarter ending during the period from March 31, 2021 to maturity, (iii) eliminates a total net leverage covenant and (iv) adds a minimum liquidity covenant tested at all times during the term of the Senior Credit Facilities. In connection with the transactions contemplated by the Term Loan Amendment, on April 6, 2020, the Company issued to the Term Loan lenders certain warrants to purchase shares of the Company’s common stock (collectively, the “Warrants”). The Warrants are exercisable for up to, in the aggregate, 5,389,949 of pre-reverse stock split shares of the Company’s common stock at an exercise price of $0.01 per share of common stock. The Warrants will become exercisable at any time after the Company implements the reverse stock split previously approved by its stockholders and will remain exercisable, in whole or in part, for a period of 5 years. The number of shares issuable upon the exercise of the Warrants is subject to customary adjustments upon the occurrence of certain events, including (i) payment of a dividend or distribution to holders of shares of the Company’s common stock payable in shares of the Company’s common stock, (ii) a subdivision, capital reorganization or reclassification of the Company’s common stock or (iii) a merger, sale or other change of control transaction. At March 31, 2020 and December 31, 2019, the net carrying value of the debt and the remaining unamortized debt discounts and debt issuance costs were as follows: March 31, 2020 December 31, 2019 Face amount of the 2023 Notes (due May 2023) $ 66,090 $ 66,090 Face amount of the Revolver Credit Facility (due December 2022) 25,000 25,000 Face amount of the 2023 Series B Notes (due May 2023) 34,405 34,405 Face amount of the 2023 Loan (due February 2023) 90,846 88,464 Total carrying value, current 216,341 213,959 Less unamortized discounts and debt issuance costs (25,994) (27,589) Total net carrying value, current $ 190,347 $ 186,370

Derivatives

Derivatives	3 Months Ended
	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives The Company accounts for its derivative instruments in accordance with ASC 815-10, “Derivatives and Hedging”. ASC 815-10 establishes accounting and reporting standards requiring that derivative instruments, including derivative instruments embedded in other contracts, be recorded on the balance sheet as either an asset or liability measured at its fair value. ASC 815-10 also requires that changes in the fair value of derivative instruments be recognized currently in results of operations unless specific hedge accounting criteria are met. The Company has not entered into hedging activities to date. The Company's derivative liability at March 31, 2020 included the embedded convertible option of its 2023 Series B Notes issued on October 31, 2019, which was recorded as a liability at fair value upon its issuance and was revalued at each reporting date, with the change in the fair value of the instruments included in the change in the derivative liabilities line on the condensed consolidated statements of operations. The terms and assumptions used in connection with the valuation of the convertible option of the 2023 Series B Notes were as follows: 12/31/2019 3/31/2020 Issuance date 10/31/2019 10/31/2019 Maturity date 5/1/2023 5/1/2023 Term (years) 3.33 3.08 Principal $ 34,405 $ 34,405 Seniority Senior unsecured Senior unsecured Conversion price $ 0.72 $ 0.72 Stock price $ 0.43 $ 0.28 Risk free rate 1.6 % 0.3 % Volatility 47.3 % 55.0 % During the first quarter of 2020, the Company recorded a derivative liability of $5.3 million associated with certain mandatory prepayment penalties and the recognition of future interest payments in the anticipation of a potential future default on its Senior Credit Facilities. The following table presents the Company’s liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2019 and March 31, 2020, respectively. Quoted Prices Significant Significant Balance Quoted Prices Significant Significant Balance Descriptions (Level 1) (Level 2) (Level 3) December 31, 2019 (Level 1) (Level 2) (Level 3) March 31, 2020 Derivative liability related to Series B Convertible Notes — — $ 6,776 $ 6,776 — — $ 2,781 $ 2,781 Derivative liabilities related to the Senior Credit Facilities — — — — — — 5,253 5,253 Derivative liabilities as of March 31, 2020 — — $ 6,776 $ 6,776 — — $ 8,034 $ 8,034 The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2020. Any unrealized gains or losses on the derivative liabilities are recorded as non-operating income or expense in the Company’s statement of operations. Descriptions Balance as of (Gain) or loss recognized in earnings Balance as of Fair value of convertible feature of Series B Convertible Notes $ 6,776 (3,995) $ 2,781 Fair value of the derivative liabilities related to the Senior Credit Facilities — 5,253 5,253 Change in the fair value of derivative liabilities for the quarter ended March 31, 2020 $ 6,776 1,258 $ 8,034

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The Company assesses the recoverability of the carrying value of goodwill on a reporting unit basis on October 1 of each year, whenever events occur or changes in circumstances indicate the carrying value of goodwill may not be recoverable. There have been no events or changes in circumstances that would indicate the carrying value of goodwill may not be recoverable through March 31, 2020. Changes in goodwill during the three months ended March 31, 2020 and the year ended December 31, 2019 were as follows: Goodwill Goodwill balance at December 31, 2018 $ 470 Foreign currency translation 21 Goodwill balance at December 31, 2019 $ 491 Foreign currency translation (37) Goodwill balance at March 31, 2020 $ 454 Intangible Assets The following sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of March 31, 2020 and December 31, 2019. March 31, 2020 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 32,823 $ (9,516) $ 23,307 10.5 Product acquisition costs 9,225 — 9,225 N/A - Indefinite lived In process research and development ("IPR&D") 255 — 255 N/A- See description below Customer relationships 3,502 (1,590) 1,912 5.6 Total $ 45,805 $ (11,106) $ 34,699 December 31, 2019 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 39,943 $ (10,885) $ 29,058 10.8 Product acquisition costs 13,103 — 13,103 N/A - Indefinite lived In-process research and development ("IPR&D") 327 — 327 N/A - Indefinite lived Customer relationships 3,658 (1,501) 2,157 5.9 Total $ 57,031 $ (12,386) $ 44,645 Changes in intangibles during the three months ended March 31, 2020 were as follows (in thousands): Trademarks and Technology Product Acquisition costs IPR&D Customer Relationships Balance at December 31, 2019 $ 29,058 $ 13,103 $ 327 $ 2,157 Amortization (652) — — (89) IPR&D placed in service Loss on impairment (4,861) (3,512) — — Foreign currency translation (238) (366) (72) (156) Balance at March 31, 2020 $ 23,307 $ 9,225 $ 255 $ 1,912 Under the provisions of ASC 360-10-55, the Company reviews its intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. The current financial results and anticipated future results of the Company have been negatively impacted due to COVID-19 and therefore the Company performed an impairment analysis for the quarter ended March 31, 2020, by comparing the expected future cash flows of the assets to the carrying value of the related intangible assets. The Company recorded impairment charges of $8.4 million in the current quarter related to trademarks and technology of $4.9 million and product acquisition costs of $3.5 million. The Company presented the $8.4 million in the impairment charges line on its condensed consolidated statements of income for the three months ended March 31, 2020, accordingly. The useful lives of the Company’s intangibles are as follows: Intangibles Category Amortizable Life Product Acquisition Costs 10 years Trademarks and Technology 15 years Customer Relationships 10 years

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock Options The Company recognized $0.4 million and $0.3 million of compensation expense related to stock options during the three months ended March 31, 2020 and 2019, respectively. On May 25, 2016, the Board of Directors approved the Company’s 2016 Equity Incentive Plan (the “2016 Plan”). On May 21, 2018, the Board of Directors adopted, and the Company’s stockholders subsequently approved, an amendment and restatement of the 2016 Plan to increase the number of shares of Common Stock available for grant under such plan by adding 2,000,000 shares of Common Stock. The 2016 Plan, as amended, provides for the issuance of awards of up to 4,000,000 shares of the Company’s common stock, plus any shares of common stock that are represented by awards granted under our Director Plan and 2009 Plan that are forfeited, expire or are canceled without delivery of shares of common stock or which result in the forfeiture of shares of common stock back to the Company on or after May 25, 2016, up to 2,500,000 shares. Generally, shares of common stock reserved for awards under the 2016 Plan that lapse or are canceled, will be added back to the share reserve available for future awards. However, shares of common stock tendered in payment for an award or shares of common stock withheld for taxes will not be available again for grant. The 2016 Plan provides that no participant may receive awards for more than 1,000,000 shares of common stock in any fiscal year. As the 2016 Plan supersedes both the Director Plan or the 2009 Plan, any available shares from both are now incorporated into the 2016 Plan. As of March 31, 2020, there were 13,612 RSUs outstanding, 185,564 shares of common stock outstanding and 4,278,773 stock options under the 2016 Plan. As of December 31, 2019, there were 62,680 RSUs outstanding, 136,496 shares of common stock outstanding and 2,835,131 stock options outstanding under the 2016 Plan. As of March 31, 2020, and December 31, 2019, there were a total of 921,089 and 2,334,731 options available under the Plan, respectively. In the interest of maintaining consistency with the Company's 2016 Equity Incentive Plan, on March 13, 2017, the Company entered into (i) an amendment to the option agreements governing each option grant currently outstanding under the Company's 2009 Equity Incentive Plan, and (ii) an amendment to the RSU, agreements governing each RSU grant currently outstanding under the 2009 Plan. The amendments provide for the automatic vesting upon a change of control of the Company of each option grant and RSU grant, as applicable, outstanding under the 2009 Plan. The amendments had a de minimis value to the holders as of March 31, 2020, and therefore no additional stock compensation expense was recognized related to the amendments. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. Three Months Ended March 31, Assumptions 2020 2019 Expected dividends — — Risk-free rate 0.85% - 1.60% 2.47 % Expected volatility 78.56% - 79.58% 57.8%-60.2% Expected term (in years) 3.2-3.3 years 3.2-3.3 years Expected volatility was calculated using the historical volatility of the Company's stock over the expected life of the options. The expected life of the options was estimated based on the Company's historical data. The risk free interest rate is based on U.S. Treasury yields for securities with terms approximating the terms of the grants. Forfeitures are recognized in the period they occur. The assumptions used in the Black-Scholes options valuation model are highly subjective, and can materially affect the resulting valuation. A summary of option activity under the 1999 Director Stock Option Plan, 2009 Equity Incentive Plan, and the 2016 Equity Incentive Plan as of March 31, 2020 and changes during the period are presented below: Number of Options Weighted Average Exercise Price Outstanding as of January 1, 2020 5,167,739 $ 3.34 Issued 3,049,178 0.41 Exercised — — Forfeited (66,588) 2.17 Expired (68,948) 4.81 Outstanding as of March 31, 2020 8,081,381 $ 2.23 Exercisable as of March 31, 2020 3,562,724 $ 4.06 The following tables summarize information regarding options outstanding and exercisable at March 31, 2020: Outstanding: Stock Weighted Weighted Range of Exercise Prices Outstanding Exercise Price Contractual Life $0.00 - $0.78 3,228,583 $ 0.42 9.85 $0.79 - $1.50 1,745,369 1.03 4.31 $1.51 - $5.50 1,835,130 2.30 7.99 $5.51 - $10.67 1,272,299 7.69 5.98 Total 8,081,381 $ 2.23 7.57 Exercisable: Range of Exercise Prices Stock Options Exercisable Weighted Average Exercise Price $0.79 - $1.50 1,370,748 $ 1.06 $1.51 - $5.50 934,052 2.56 $5.51 - $10.67 1,257,924 8.45 Total 3,562,724 $ 4.06 As of March 31, 2020, the intrinsic value of the options outstanding was none, and none of the options were exercisable. As of March 31, 2020, there was $1.2 million of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the Plan. The costs will be recognized through February 2023. Restricted Stock and RSUs The Company periodically grants restricted stock and RSU awards to certain officers and other employees that typically vest one Number of RSUs Weighted Average Grant Date Fair Value Non-vested balance at January 1, 2020 62,680 $ 4.07 Changes during the period: Shares granted — — Shares vested (49,068) 4.36 Shares forfeited — — Non-vested balance at March 31, 2020 13,612 $ 3.03

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company’s income tax expense was $0.05 million and $0.01 million for the three months ended March 31, 2020 and 2019, with effective tax rates of 0.19% and 0.09%, respectively. The Company excludes from the calculation of the effective tax rate any entities that are projected to operate at a loss, have no tax benefit that can reasonably be expected, and those entities which operate in a zero tax rate jurisdiction. Due to continuing operating losses in the United States, the tax provision is based on minimum U.S. state income taxes and the operations of certain foreign affiliates that are subject to taxes in their respective countries. On March 27, 2020, the president signed into law the Coronavirus Aid, Relief, and Economic Security Act (CARES) providing nearly $2 trillion in economic relief to eligible businesses impacted by the coronavirus outbreak. The Company is currently studying its options under the CARES Act. Tax implications of the CARES Act include expansion of the business interest expense deduction from 30% to 50% for the years 2019 and 2020 and the suspension of the 80% limitation on usage of Net Operating Losses incurred in the years 2018 through 2020. The Company’s net interest expense is subject to limitation under Section 163(j). The limitation serves to reduce the net operating loss and create an additional attribute for the disallowed net interest expense. Therefore, there is no effect on earnings. The foreign entities of the Company are projected to generate an additional operating loss for the year 2020. Therefore, the Company has not made any adjustments related to potential GILTI tax in its financial statements. The Company evaluates the recoverability of its net deferred tax assets based on its history of operating results, its expectations for the future and expiration dates of its attributes including operating losses. The Company has concluded that it is more likely than not it will be unable to realize the net deferred tax assets in the immediate future and has established a valuation allowance for all U.S. and foreign net deferred tax assets. At December 31, 2019, the Company’s U.S. federal net operating loss carryforwards totaled $48.5 million. The Company’s ability to use net operating loss carry forwards is subject to limitation in future periods under certain provisions of Section 382 of the Internal Revenue Code of 1986, as amended, which limit the utilization of net operating losses upon a more than 50% change in ownership of the Company’s stock. The Company examined the application of Section 382 with respect to an ownership change that took place during 2010, as well as the limitation on the application of net operating loss carry forwards. The Company believes that net operating losses subsequent to the change date in 2010 are not subject to Section 382 limitations. The Company’s net loss carryforwards may be further limited in the future if additional ownership changes occur. The Company is subject to the provisions of ASC 740-10-25, “ Income Taxes” (ASC 740) which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. On a quarterly basis, the Company undergoes a process to evaluate whether income tax accruals are in accordance with ASC 740 guidance on uncertain tax positions. For federal purposes, post 1998 tax years remain open to examination as a result of net operating loss carryforwards. The Company is currently open to audit by the appropriate state income taxing authorities for tax years 2015 to 2018. The Company has not recorded any liability for uncertain tax positions.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2020
Other Income and Expenses [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses represent various obligations of the Company including certain operating expenses and taxes payable. As of March 31, 2020 and December 31, 2019, the largest components of accrued expenses were: March 31, 2020 December 31, 2019 Interest expense $ 2,998 $ 1,539 Payroll 2,127 1,789 Professional fees 2,140 1,881 Wholesaler fees 687 747 Medicaid and Medicare rebates 863 987 Rebates 606 774 Royalties 85 377 Clinical studies 334 334 Income Tax 19 20 Capital expenditures 77 23 Inventory and Supplies 258 250 Other 200 564 $ 10,394 $ 9,285

Legal and U.S. Regulatory Proce

Legal and U.S. Regulatory Proceedings	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Legal and U.S. Regulatory Proceedings	Legal and U.S. Regulatory Proceedings To date, thirteen putative class action antitrust lawsuits have been filed against the Company along with co-defendants, including Taro Pharmaceuticals U.S.A., Inc. and Perrigo New York Inc., regarding the pricing of generic pharmaceuticals, including econazole nitrate. The class plaintiffs seek to represent nationwide or state classes consisting of persons who directly purchased, indirectly purchased, paid and/or reimbursed patients for the purchase of generic pharmaceuticals from as early as July 1, 2009 until the time the defendants’ allegedly unlawful conduct ceased or will cease. The class plaintiffs seek treble damages for alleged overcharges during the alleged period of conspiracy, and certain of the class plaintiffs also seek injunctive relief against the defendants. The actions have been consolidated by the Judicial Panel on Multidistrict Litigation to the Eastern District of Pennsylvania for pre-trial proceedings as part of the In re Generic Pharmaceuticals Pricing Antitrust Litigation matter. On October 16, 2018 the court dismissed the class plaintiffs’ claims against the Company with leave to replead. On December 21, 2018 the class plaintiffs filed amended complaints, which the Company moved to dismiss on February 21, 2019. This motion remains pending. On December 19, 2019 certain class plaintiffs filed a further complaint that included additional claims against the Company based on the Company’s sales of fluocinolone acetonide. A motion to dismiss this complaint has not yet been filed. “Opt-out” antitrust lawsuits have additionally been filed against the Company by various plaintiffs, including Humana Inc.; The Kroger Co. et al.; United HealthCare Services, Inc.; Molina Healthcare, Inc.; MSP Recovery Claims, Series LLC; Health Care Service Corp.; and Harris County, Texas. These complaints have been consolidated into the In re Generic Pharmaceuticals Pricing Antitrust Litigation matter by the Judicial Panel on Multidistrict Litigation. Each of the opt-out complaints names up to forty-seven defendants (including the Company) and involves allegations regarding the pricing of econazole along with up to 180 other drug products, most of which were not manufactured or sold by the Company during the period at issue. The opt-out plaintiffs seek treble damages for alleged overcharges for the drug products identified in the complaint during the alleged period of conspiracy, and some also seek injunctive relief. A motion to dismiss the Humana Inc. and The Kroger Co., et al. opt-out complaints was filed on February 21, 2019. A motion to dismiss the remaining opt-out complaints has not yet been filed. Due to the early stage of these cases, the Company is unable to form a judgment at this time as to whether an unfavorable outcome is either probable or remote or to provide an estimate of the amount or range of potential loss. The Company believes these cases are without merit and it intends to vigorously defend against these claims. On October 20, 2017, a Demand for Arbitration was filed with the American Arbitration Association by Stayma Consulting Services, Inc. (“Stayma”) against the Company regarding the Company’s development and manufacture for Stayma of two generic drug products, one a lotion and one a cream, containing 0.05% of the active pharmaceutical ingredient flurandrenolide. The Company developed the two products and Stayma purchased commercial quantities of each; however, Stayma alleges that the Company breached agreements between the parties by developing an additional and different generic drug product, an ointment, containing flurandrenolide, and failing to meet certain contractual requirements. Stayma seeks monetary damages. The arbitrator has issued an interim award finding that the Company is not liable to Stayma on two of Stayma’s three claims against the Company. The third claim will proceed to a damages phase. The Company has argued that Stayma did not suffer any damages related to this claim and will vigorously pursue complete dismissal of the third claim. In addition, the arbitrator will determine money damages owed by Stayma to the Company relating to Stayma’s failure to pay several past due invoices of approximately $1.7 million. On December 13, 2018, Valdepharm SA filed a lawsuit alleging that the Company breached contracts regarding two drug products that the Company had sought to have Valdepharm manufacture. On February 12, 2019 the Company answered the complaint and counterclaimed, alleging that Valdepharm breached the contracts by failing to perform its work in compliance with FDA regulations and current Good Manufacturing Practices. Each party seeks damages associated with the alleged breach and related claims. On April 23, 2020 the court largely denied Valdepharm’s motion to dismiss Teligent’s counterclaims. Due to the early stage of the case the Company is unable to form a judgment at this time as to whether an unfavorable outcome is either probable or remote or to provide an estimate of the amount or range of potential loss. The Company believes the claims against Teligent are without merit, and it intends to vigorously defend against them. On April 15, 2019 a federal class action was filed the Oklahoma Police Pension Fund and Retirement System against the Company and certain individual defendants in the U.S. District Court, Southern District of New York. The lawsuit was brought on behalf of persons or entities who purchased or otherwise acquired publicly-traded Teligent, Inc. securities from March 7, 2017 through November 6, 2017. The complaint alleges that defendants made false or misleading statements regarding the Company’s business, operational, and compliance policies in violation of U.S. securities laws. The plaintiff seeks to recover compensable damages. Due to the early stage of these cases, the Company is unable to

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company received $3.3 million of proceeds from the U.S. Small Business Administration Paycheck Protection Program (PPP) in May and plans to balance the employee-related actions previously taken with the needs of the business to ensure a portion of the loan will be forgiven. In the meantime, the Company also initiated a company-wide cost reduction initiative targeted at eliminating discretionary spending and ensuring that remaining expenditures are reduced in line with the lower demand for our products in light of COVID-19 impact to the business. The Company's Executive Leadership Team and all employees with annual salaries exceeding 100,000 accepted a 20% and 15% eight-week reduction in pay, respectively, beginning May 4, 2020. Over the same eight-week period, the Company furloughed a portion of employees at our Buena, NJ manufacturing facility. On May 26, 2020, the Company announced that it will effect a one-for-ten reverse stock split of its outstanding common stock, which will be effective for trading purposes as of the commencement of trading on May 28, 2020. The reverse stock split reduces the number of shares outstanding from approximately 53.9 million shares of common stock to approximately 5.4 million shares of common stock post-reverse split. The number of outstanding options and warrants will also be adjusted accordingly. The number of authorized shares of common stock and the par value per share will remain unchanged. All prior period share amounts will be retroactively adjusted to reflect the reverse stock split.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair presentation of the results for the interim periods of the fiscal years ending December 31, 2020 and 2019. Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the accompanying unaudited condensed consolidated financial statements should be read in conjunction with the notes to the audited consolidated financial statements contained in the Company’s Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on April 13, 2020. Principles of Consolidation
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the valuation of derivative liabilities associated with certain Notes and the Senior Credit Facility, sales returns and allowances, allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related valuation allowances, stock based compensation, the assessment for the impairment of long-lived assets (including intangibles, goodwill and property, plant and equipment), property, plant and equipment and legal accruals for environmental cleanup and remediation costs. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid instruments purchased with the original maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. Cash and cash equivalents include cash on hand and bank demand deposits used in the Company’s cash management program.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, trade receivables, restricted cash, accounts payable and other accrued liabilities at March 31, 2020 approximate their fair value for all periods presented. The Company measures fair value in accordance with ASC 820-10, “Fair Value Measurements and Disclosures”. ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820-10 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
Loss Per Common Share	Loss Per Common Share
Concentration of Credit Risk	Concentration of Credit Risk
Recently Adopted Accounting Pronouncements/Recently Issued Not Yet Adopted Accounting Pronouncements	Recently Issued Not Yet Adopted Accounting Pronouncements In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU No. 2020-04”). The update provides optional guidance for a limited period to ease the potential burden in accounting for (or recognizing the effects of) contract modifications on financial reporting caused by reference rate reform. ASU 2020-04 is effective for all entities as of March 12, 2020 through December 31, 2022. The Company is evaluating the impact upon adoption of the update on its Condensed Consolidated Financial Statements and related disclosures. In December 2019, the FASB issued an accounting standard update to simplify the accounting for income taxes. The standard’s amendments include changes in various subtopics of accounting for income taxes including, but not limited to, accounting for “hybrid” tax regimes, tax basis step-up in goodwill obtained in a transaction that is not a business combination, intraperiod tax allocation exception to an incremental approach, ownership changes in investments, interim-period accounting for enacted changes in tax law, and year-to-date loss limitation in interim-period tax accounting. The guidance is effective for fiscal years beginning after December 15, 2020 with early adoption permitted, including the interim periods within those years. The Company is evaluating the impact this guidance will have on the Company’s Condensed Consolidated Financial Statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU No. 2016-13”), which requires that a financial asset (or a group of financial assets) measured at an amortized cost basis be presented at the net amount expected to be collected. This approach to estimating credit losses applies to most financial assets measured at amortized cost and certain other instruments, including but not limited to, trade and other receivables. The amendments in this update are initially effective for public business entities for fiscal years beginning after December 15, 2019. The Financial Accounting Standards Board subsequently postponed the effective date for small reporting companies to January 2023, which for the Company means January 1, 2023. Based on the current status of the evaluation, the Company believes the adoption of the guidance will not have a material impact on its Condensed Consolidated Financial Statements and related disclosures. The Company expects to continue and finalize its evaluation and assessment as required by the guidance upon adoption.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Restrictions on Cash and Cash Equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheet to the total amounts in the Condensed Consolidated Statement of Cash Flows as follows: March 31, 2020 March 31, 2019 Cash and cash equivalents $ 11,028 $ 6,397 Restricted cash 206 206 Restricted cash in other assets 468 472 Cash, cash equivalents and restricted cash in the statement of cash flows $ 11,702 $ 7,075
Schedule of Earnings Per Share, Basic and Diluted	For the three months ended March 31, 2020, the potential dilutive common stock equivalents have been excluded from the computation of diluted loss per share, as their effect would have been anti-dilutive. (in thousands except shares and per share data) Three months ended March 31, 2020 2019 Basic loss per share computation: Net loss - basic and diluted $ (26,836) $ (8,724) Weighted average common shares - basic and diluted 53,879,333 53,805,983 Basic and diluted loss per share $ (0.50) $ (0.16)

Revenues, Recognition and All_2

Revenues, Recognition and Allowances (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenues	Net revenues for the three months ended March 31, 2020 and 2019 were as follows: Three months ended March 31, 2020 2019 Company product sales $ 7,139 $ 12,495 Contract manufacturing sales 197 542 Research and development services and other income $ 111 $ 85 Revenue, net $ 7,447 $ 13,122 Disaggregated information for the Company product sales revenue has been recognized in the accompanying unaudited interim Condensed Consolidated Statements of Operations and is presented below according to contract type: Three months ended March 31, Company Product Sales 2020 2019 Topical $ 5,380 $ 9,032 Injectables 1,759 3,463 Total $ 7,139 $ 12,495
Schedule of Accounts, Notes, Loans and Financing Receivable	The Company's adjustments for the deductions to gross product sales are as follows: Three months ended March 31, 2020 2019 Gross product sales $ 23,166 $ 27,414 Deduction to gross product sales: Chargebacks and billbacks 11,955 10,886 Wholesaler fees for service 1,142 1,766 Sales discounts and other allowances 2,930 2,267 Total reduction to gross product sales $ 16,027 $ 14,919 Company product sales, net $ 7,139 $ 12,495

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories are valued at the lower of cost or net realizable value and using the first-in-first-out method. Inventories as of March 31, 2020 and December 31, 2019 consisted of: March 31, 2020 December 31, 2019 Raw materials $ 15,221 $ 14,117 Work in progress 217 133 Finished goods 17,704 10,989 Inventories reserve (3,600) (2,208) Inventories, net $ 29,542 $ 23,031

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment consists of the following: March 31, 2020 December 31, 2019 Land $ 401 $ 401 Building and improvements 58,969 58,959 Machinery and equipment 14,961 14,897 Computer hardware and software 4,814 4,771 Furniture and fixtures 702 705 Construction in progress 31,694 30,759 111,541 110,492 Less accumulated depreciation and amortization (15,119) (14,143) Property, plant and equipment, net $ 96,422 $ 96,349

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Components of Lease Expense	The components of lease expense were as follows: Three months ended Three months ended Operating lease cost $ 158 $ 159 Finance lease cost: Amortization of right-of-use assets 4 3 Interest on lease liabilities 1 2 Total finance lease cost $ 5 $ 5
Summary of Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases as of the periods presented were as follows: March 31, 2020 December 31, 2019 Operating Leases Other assets $ 2,321 $ 2,453 Other current liabilities 438 434 Other long-term liabilities 2,053 2,199 Total operating lease liabilities 2,491 2,633 Finance Leases Property, plant, and equipment 81 81 Accumulated depreciation (18) (12) Property, plant, and equipment, net 63 69 Other current liabilities 13 12 Other long-term liabilities 54 57 Total finance lease liabilities $ 67 $ 69
Schedule of Finance Lease Liabilities by Maturity	As of March 31, 2020, maturities of lease liabilities were as follows: Operating Financing Year Ending December 31, Leases Leases Remainder of 2020 $ 466 $ 14 2021 602 18 2022 546 18 2023 545 18 2024 232 12 2025 204 — Thereafter 622 — Total lease payments 3,217 80 Less imputed interest 726 13 Total $ 2,491 $ 67
Summary of Operating Leases by Maturity	As of March 31, 2020, maturities of lease liabilities were as follows: Operating Financing Year Ending December 31, Leases Leases Remainder of 2020 $ 466 $ 14 2021 602 18 2022 546 18 2023 545 18 2024 232 12 2025 204 — Thereafter 622 — Total lease payments 3,217 80 Less imputed interest 726 13 Total $ 2,491 $ 67

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Convertible Debt	At March 31, 2020 and December 31, 2019, the net carrying value of the debt and the remaining unamortized debt discounts and debt issuance costs were as follows: March 31, 2020 December 31, 2019 Face amount of the 2023 Notes (due May 2023) $ 66,090 $ 66,090 Face amount of the Revolver Credit Facility (due December 2022) 25,000 25,000 Face amount of the 2023 Series B Notes (due May 2023) 34,405 34,405 Face amount of the 2023 Loan (due February 2023) 90,846 88,464 Total carrying value, current 216,341 213,959 Less unamortized discounts and debt issuance costs (25,994) (27,589) Total net carrying value, current $ 190,347 $ 186,370

Derivatives (Tables)

Derivatives (Tables)	3 Months Ended
	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Terms and Assumptions in Valuation of Convertible Option of Notes	The terms and assumptions used in connection with the valuation of the convertible option of the 2023 Series B Notes were as follows: 12/31/2019 3/31/2020 Issuance date 10/31/2019 10/31/2019 Maturity date 5/1/2023 5/1/2023 Term (years) 3.33 3.08 Principal $ 34,405 $ 34,405 Seniority Senior unsecured Senior unsecured Conversion price $ 0.72 $ 0.72 Stock price $ 0.43 $ 0.28 Risk free rate 1.6 % 0.3 % Volatility 47.3 % 55.0 %
Schedule of Liabilities Measured and Recognized at Fair Value on a Recurring Basis	The following table presents the Company’s liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2019 and March 31, 2020, respectively. Quoted Prices Significant Significant Balance Quoted Prices Significant Significant Balance Descriptions (Level 1) (Level 2) (Level 3) December 31, 2019 (Level 1) (Level 2) (Level 3) March 31, 2020 Derivative liability related to Series B Convertible Notes — — $ 6,776 $ 6,776 — — $ 2,781 $ 2,781 Derivative liabilities related to the Senior Credit Facilities — — — — — — 5,253 5,253 Derivative liabilities as of March 31, 2020 — — $ 6,776 $ 6,776 — — $ 8,034 $ 8,034 The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2020. Any unrealized gains or losses on the derivative liabilities are recorded as non-operating income or expense in the Company’s statement of operations. Descriptions Balance as of (Gain) or loss recognized in earnings Balance as of Fair value of convertible feature of Series B Convertible Notes $ 6,776 (3,995) $ 2,781 Fair value of the derivative liabilities related to the Senior Credit Facilities — 5,253 5,253 Change in the fair value of derivative liabilities for the quarter ended March 31, 2020 $ 6,776 1,258 $ 8,034

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes in goodwill during the three months ended March 31, 2020 and the year ended December 31, 2019 were as follows: Goodwill Goodwill balance at December 31, 2018 $ 470 Foreign currency translation 21 Goodwill balance at December 31, 2019 $ 491 Foreign currency translation (37) Goodwill balance at March 31, 2020 $ 454
Schedule of Finite-Lived Intangible Assets	The following sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of March 31, 2020 and December 31, 2019. March 31, 2020 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 32,823 $ (9,516) $ 23,307 10.5 Product acquisition costs 9,225 — 9,225 N/A - Indefinite lived In process research and development ("IPR&D") 255 — 255 N/A- See description below Customer relationships 3,502 (1,590) 1,912 5.6 Total $ 45,805 $ (11,106) $ 34,699 December 31, 2019 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 39,943 $ (10,885) $ 29,058 10.8 Product acquisition costs 13,103 — 13,103 N/A - Indefinite lived In-process research and development ("IPR&D") 327 — 327 N/A - Indefinite lived Customer relationships 3,658 (1,501) 2,157 5.9 Total $ 57,031 $ (12,386) $ 44,645 Changes in intangibles during the three months ended March 31, 2020 were as follows (in thousands): Trademarks and Technology Product Acquisition costs IPR&D Customer Relationships Balance at December 31, 2019 $ 29,058 $ 13,103 $ 327 $ 2,157 Amortization (652) — — (89) IPR&D placed in service Loss on impairment (4,861) (3,512) — — Foreign currency translation (238) (366) (72) (156) Balance at March 31, 2020 $ 23,307 $ 9,225 $ 255 $ 1,912
Schedule of Indefinite-Lived Intangible Assets	The following sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of March 31, 2020 and December 31, 2019. March 31, 2020 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 32,823 $ (9,516) $ 23,307 10.5 Product acquisition costs 9,225 — 9,225 N/A - Indefinite lived In process research and development ("IPR&D") 255 — 255 N/A- See description below Customer relationships 3,502 (1,590) 1,912 5.6 Total $ 45,805 $ (11,106) $ 34,699 December 31, 2019 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 39,943 $ (10,885) $ 29,058 10.8 Product acquisition costs 13,103 — 13,103 N/A - Indefinite lived In-process research and development ("IPR&D") 327 — 327 N/A - Indefinite lived Customer relationships 3,658 (1,501) 2,157 5.9 Total $ 57,031 $ (12,386) $ 44,645 Changes in intangibles during the three months ended March 31, 2020 were as follows (in thousands): Trademarks and Technology Product Acquisition costs IPR&D Customer Relationships Balance at December 31, 2019 $ 29,058 $ 13,103 $ 327 $ 2,157 Amortization (652) — — (89) IPR&D placed in service Loss on impairment (4,861) (3,512) — — Foreign currency translation (238) (366) (72) (156) Balance at March 31, 2020 $ 23,307 $ 9,225 $ 255 $ 1,912
Schedule Of Intangible Assets, Useful Life	The useful lives of the Company’s intangibles are as follows: Intangibles Category Amortizable Life Product Acquisition Costs 10 years Trademarks and Technology 15 years Customer Relationships 10 years

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Valuation Assumptions	The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. Three Months Ended March 31, Assumptions 2020 2019 Expected dividends — — Risk-free rate 0.85% - 1.60% 2.47 % Expected volatility 78.56% - 79.58% 57.8%-60.2% Expected term (in years) 3.2-3.3 years 3.2-3.3 years
Schedule of Stock Option Activity	A summary of option activity under the 1999 Director Stock Option Plan, 2009 Equity Incentive Plan, and the 2016 Equity Incentive Plan as of March 31, 2020 and changes during the period are presented below: Number of Options Weighted Average Exercise Price Outstanding as of January 1, 2020 5,167,739 $ 3.34 Issued 3,049,178 0.41 Exercised — — Forfeited (66,588) 2.17 Expired (68,948) 4.81 Outstanding as of March 31, 2020 8,081,381 $ 2.23 Exercisable as of March 31, 2020 3,562,724 $ 4.06
Schedule of Stock Options Outstanding and Exercisable	The following tables summarize information regarding options outstanding and exercisable at March 31, 2020: Outstanding: Stock Weighted Weighted Range of Exercise Prices Outstanding Exercise Price Contractual Life $0.00 - $0.78 3,228,583 $ 0.42 9.85 $0.79 - $1.50 1,745,369 1.03 4.31 $1.51 - $5.50 1,835,130 2.30 7.99 $5.51 - $10.67 1,272,299 7.69 5.98 Total 8,081,381 $ 2.23 7.57 Exercisable: Range of Exercise Prices Stock Options Exercisable Weighted Average Exercise Price $0.79 - $1.50 1,370,748 $ 1.06 $1.51 - $5.50 934,052 2.56 $5.51 - $10.67 1,257,924 8.45 Total 3,562,724 $ 4.06
Schedule of Nonvested Restricted Stock Units Activity	The following table summarizes the number of unvested RSUs and their weighted average exercise price for the three months ended March 31, 2020. Number of RSUs Weighted Average Grant Date Fair Value Non-vested balance at January 1, 2020 62,680 $ 4.07 Changes during the period: Shares granted — — Shares vested (49,068) 4.36 Shares forfeited — — Non-vested balance at March 31, 2020 13,612 $ 3.03

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
Other Income and Expenses [Abstract]
Schedule of Accrued Expenses	As of March 31, 2020 and December 31, 2019, the largest components of accrued expenses were: March 31, 2020 December 31, 2019 Interest expense $ 2,998 $ 1,539 Payroll 2,127 1,789 Professional fees 2,140 1,881 Wholesaler fees 687 747 Medicaid and Medicare rebates 863 987 Rebates 606 774 Royalties 85 377 Clinical studies 334 334 Income Tax 19 20 Capital expenditures 77 23 Inventory and Supplies 258 250 Other 200 564 $ 10,394 $ 9,285

Nature of the Business and Li_2

Nature of the Business and Liquidity (Details) $ in Thousands	1 Months Ended	3 Months Ended
	May 26, 2020USD ($)	Mar. 31, 2020USD ($)productsegment	Mar. 31, 2019USD ($)	May 04, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Summary of Significant Accounting Policies Details [Line Items]
Segments | segment		1
Impairment charges		$ 8,373	$ 0
Accumulated deficit		148,310			$ 121,474
Principal amount of outstanding borrowings		190,300
Cash, cash equivalents and restricted cash in the statement of cash flows		11,702	$ 7,075		$ 16,182	$ 13,069
Derivative liability		5,300
Subsequent Event
Summary of Significant Accounting Policies Details [Line Items]
Proceeds received under PPP	$ 3,300
Annual salary amount, reduction in pay				$ 100
Subsequent Event | Executive Leadership Team
Summary of Significant Accounting Policies Details [Line Items]
Percentage of pay reduction				20000000.00%
Subsequent Event | All Employees
Summary of Significant Accounting Policies Details [Line Items]
Percentage of pay reduction				15000000.00%
Product acquisition costs
Summary of Significant Accounting Policies Details [Line Items]
Loss on impairment of intangible assets		3,512
Trademarks and Technology
Summary of Significant Accounting Policies Details [Line Items]
Impairment charges, finite-lived		$ 4,861
United States
Summary of Significant Accounting Policies Details [Line Items]
Generic products marketed | product		38
Branded generic products marketed | product		4
Canada
Summary of Significant Accounting Policies Details [Line Items]
Generic and branded products marketed | product		32

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 11,028	$ 15,508	$ 6,397
Restricted cash	206	206	206
Restricted cash in other assets	468		472
Cash, cash equivalents and restricted cash in the statement of cash flows	$ 11,702	$ 16,182	$ 7,075	$ 13,069

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Jan. 31, 2019
Summary of Significant Accounting Policies Details [Line Items]
Derivative liability	$ 5,300
Revenue, net	23,166	$ 27,414
Assets	186,946		$ 206,905
Convertible Note 2019
Summary of Significant Accounting Policies Details [Line Items]
Restricted cash				$ 2,700
Domestic
Summary of Significant Accounting Policies Details [Line Items]
Revenue, net	5,600	9,700
Assets	146,400	135,500
Foreign
Summary of Significant Accounting Policies Details [Line Items]
Revenue, net	1,800	3,400
Assets	$ 40,500	$ 56,400
Sales Revenue
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk	16.90%	48.00%
Sales Revenue | Customer One
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk		30.00%
Sales Revenue | Customer Two
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk		18.00%
Accounts Receivable
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk	12.00%	37.00%
(Level 2) | Estimate of Fair Value Measurement | 2023 Term Loans
Summary of Significant Accounting Policies Details [Line Items]
Debt instrument, fair value disclosure	$ 24,800
(Level 2) | Estimate of Fair Value Measurement | Series B Senior Unsecured Convertible Notes
Summary of Significant Accounting Policies Details [Line Items]
Debt instrument, fair value disclosure	22,100
(Level 2) | Reported Value Measurement | 2023 Term Loans
Summary of Significant Accounting Policies Details [Line Items]
Debt instrument, fair value disclosure	53,900
(Level 3) | Reported Value Measurement
Summary of Significant Accounting Policies Details [Line Items]
Derivative liability	$ 2,800

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Computation of Earnings (Loss) per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Basic loss per share computation:
Net loss	$ (26,836)	$ (8,724)
Weighted average common shares - basic and diluted (in shares)	53,879,333	53,805,983
Basic and diluted loss per share (in dollars per share)	$ (0.50)	$ (0.16)

Revenues, Recognition and All_3

Revenues, Recognition and Allowances - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)transaction_typesegmentproduct	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)
Disaggregation of Revenue [Line Items]
Types of transactions | transaction_type	3
Segments | segment	1
Allowance for doubtful accounts	$ 2.3		$ 2.2
Allowance for doubtful accounts related to one customer	$ 1.7		1.7
Accounts receivable, terms of customer credit	100 days
Percentage of net sales for royalty	40.00%
Royalty expense	$ 0.1	$ 0.3
United States
Disaggregation of Revenue [Line Items]
Products manufactured, marketed and distributed | product	4
Net Of SRA Balance
Disaggregation of Revenue [Line Items]
Accounts receivable	$ 23.4		$ 30.5

Revenues, Recognition and All_4

Revenues, Recognition and Allowances - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue, net	$ 7,447	$ 13,122
Company product sales
Disaggregation of Revenue [Line Items]
Revenue, net	7,139	12,495
Contract manufacturing sales
Disaggregation of Revenue [Line Items]
Revenue, net	197	542
Research and development services and other income
Disaggregation of Revenue [Line Items]
Revenue, net	111	85
Topical
Disaggregation of Revenue [Line Items]
Revenue, net	5,380	9,032
Injectables
Disaggregation of Revenue [Line Items]
Revenue, net	$ 1,759	$ 3,463

Revenues, Recognition and All_5

Revenues, Recognition and Allowances - Adjustments to Gross Product Sales (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Gross product sales	$ 23,166	$ 27,414
Deduction to gross product sales:
Chargebacks and billbacks	11,955	10,886
Wholesaler fees for service	1,142	1,766
Sales discounts and other allowances	2,930	2,267
Total reduction to gross product sales	16,027	14,919
Company product sales, net	7,447	13,122
Company product sales
Deduction to gross product sales:
Company product sales, net	$ 7,139	$ 12,495

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 15,221	$ 14,117
Work in progress	217	133
Finished goods	17,704	10,989
Inventories reserve	(3,600)	(2,208)
Inventories, net	$ 29,542	$ 23,031

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property plant and equipment	$ 111,541	$ 110,492
Less accumulated depreciation and amortization	(15,119)	(14,143)
Property, plant and equipment, net	96,422	96,349
Land
Property, Plant and Equipment [Line Items]
Property plant and equipment	401	401
Building and improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment	58,969	58,959
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment	14,961	14,897
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment	4,814	4,771
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment	702	705
Construction in progress
Property, Plant and Equipment [Line Items]
Property plant and equipment	$ 31,694	$ 30,759

Property, Plant and Equipment_2

Property, Plant and Equipment - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 985	$ 876
Construction in progress
Property, Plant and Equipment [Line Items]
Payroll costs	$ 300

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Operating lease right-of-use asset	$ 2,321,000		$ 2,453,000
Operating lease liability	$ 2,491,000		$ 2,633,000
Lease renewal term	5 years
Right-of-use assets obtained in exchange for operating lease liabilities	$ 0	$ 1,000,000
Operating lease payments	$ 100,000	$ 100,000
Operating lease, weighted average remaining lease term	6 years 1 month 6 days
Finance lease, weighted average remaining lease term	4 years 4 months 24 days
Operating lease, weighted average discount rate	8.30%
Finance lease, weighted average discount rate	8.00%
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year
Weighted average discount rate	4.86%
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	9 years
Weighted average discount rate	8.60%

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating lease cost	$ 158	$ 159
Amortization of right-of-use assets	4	3
Interest on lease liabilities	1	2
Total finance lease cost	$ 5	$ 5

Leases - Balance Sheet Informat

Leases - Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease right-of-use asset	$ 2,321	$ 2,453
Other current liabilities	438	434
Operating lease liabilities	2,053	2,199
Total operating lease liabilities	2,491	2,633
Property, plant, and equipment	81	81
Accumulated depreciation	(18)	(12)
Property, plant, and equipment, net	63	69
Other current liabilities	13	12
Other long-term liabilities	54	57
Total finance lease liabilities	$ 67	$ 69

Leases - Schedule of Maturities

Leases - Schedule of Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Operating Lease Liabilities, Payments Due [Abstract]
Remainder of 2020	$ 466
2020	602
2022	546
2022	545
2023	232
2024	204
Thereafter	622
Total lease payments	3,217
Less imputed interest	726
Total	2,491	$ 2,633
Finance Lease Liabilities, Payments, Due [Abstract]
Remainder of 2020	14
2021	18
2021	18
2023	18
2024	12
2025	0
Thereafter	0
Total lease payments	80
Less imputed interest	13
Total	$ 67	$ 69

Debt - Narrative (Details)

Debt - Narrative (Details)	Apr. 06, 2020USD ($)$ / sharesshares	Oct. 31, 2019USD ($)$ / shares	Sep. 18, 2019USD ($)	Dec. 21, 2018USD ($)	Dec. 13, 2018USD ($)loan	Apr. 27, 2018USD ($)$ / shares	Dec. 31, 2019USD ($)$ / shares	Nov. 30, 2019USD ($)	Apr. 30, 2019USD ($)	Jan. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Mar. 31, 2020USD ($)$ / shares	Sep. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2020USD ($)$ / shares	Dec. 22, 2014USD ($)	Dec. 16, 2014USD ($)
Debt Instrument [Line Items]
Non cash interest expense												$ 1,984,000		$ 2,020,000
Partial extinguishment of equity component												(7,600,000)
Debt partial extinguishment												0		185,000
Proceeds from Revolver												0		$ 5,000,000
Derivative liability												5,300,000			$ 5,300,000
Remeasured derivative liability							$ 6,776,000					8,034,000			8,034,000
Subsequent Event
Debt Instrument [Line Items]
Pre-reverse stock split shares (in shares) | shares	5,389,949
Exercise price (dollars per share) | $ / shares	$ 0.01
Period warrants are exercisable	5 years
Convertible Notes Payable
Debt Instrument [Line Items]
Face amount of the Notes							213,959,000					216,341,000			216,341,000
Carrying value of original debt							186,370,000					190,347,000			190,347,000
2023 Series A Unsecured Convertible Notes for Series B Senior Unsecured Convertible Notes
Debt Instrument [Line Items]
Debt issuance costs												1,400,000			1,400,000
Derivative liability												13,500,000			13,500,000
Remeasured derivative liability												2,800,000			2,800,000
Gain on change in fair value of derivative												4,000,000
Loss on restructuring												900,000
Line of Credit
Debt Instrument [Line Items]
Proceeds from Revolver											$ 52,800,000
Line of Credit | Subsequent Event
Debt Instrument [Line Items]
Interest rate, effective percentage	4.25%
Liquidity covenant compliance	$ 10,000,000
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Face amount of the Notes							25,000,000					25,000,000			25,000,000
Debt issuance costs												300,000			300,000
Unamortized discount												500,000			500,000
Proceeds from Revolver			$ 2,500,000		$ 15,000,000				$ 5,000,000	$ 5,000,000
Line of credit maximum borrowing capacity					25,000,000							25,000,000			25,000,000
Remeasured derivative liability							0					$ 5,253,000			$ 5,253,000
Repayment fee								$ 100,000
Line of Credit | Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Interest rate, effective percentage												6.20%			6.20%
Line of Credit | Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Interest rate, effective percentage												9.10%			9.10%
Line of Credit | Revolving Credit Facility | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Basis spread on variable rate												3.75%
Line of Credit | Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
Line of Credit | Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate	5.50%
Line of Credit | Revolving Credit Facility | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate												2.75%
Line of Credit | Revolving Credit Facility | Base Rate | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate	4.50%
Line of Credit | Term Loan
Debt Instrument [Line Items]
Face amount of the Notes					$ 80,000,000
Debt issuance costs												$ 800,000			$ 800,000
Unamortized discount												1,800,000			1,800,000
Covenant, revenue required to attain												$ 125,000,000
Line of Credit | Term Loan | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Basis spread on variable rate												8.75%
Line of Credit | Term Loan | London Interbank Offered Rate (LIBOR) | Minimum | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
Line of Credit | Term Loan | London Interbank Offered Rate (LIBOR) | Maximum | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate	13.00%
Line of Credit | Term Loan | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate												7.75%
Line of Credit | Term Loan | Base Rate | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate	12.00%
Qualified Institutional Buyers
Debt Instrument [Line Items]
Face amount of the Notes																$ 18,750,000	$ 125,000,000
Convertible Note 2019
Debt Instrument [Line Items]
Non cash interest expense												$ 2,500,000
Convertible Note 2019 | Convertible Notes Payable
Debt Instrument [Line Items]
Stated interest rate																3.75%	3.75%
Debt, transfer						$ 75,100,000
Debt partial extinguishment						$ 75,100,000
Convertible Note 2023 | Convertible Notes Payable
Debt Instrument [Line Items]
Stated interest rate						4.75%
Debt, transfer						$ 75,100,000
Conversion price | $ / shares						$ 4.45
Settlement conversion price (dollars per share) | $ / shares						$ 280.90
Debt issuance costs						$ 1,600,000
Unamortized discount						$ 19,000,000
Interest rate, effective percentage						11.90%
Senior Notes, due December 2019
Debt Instrument [Line Items]
Partial extinguishment of equity component											2,900,000
Loss on extinguishment of debt											1,700,000		$ 200,000
Senior Notes, due December 2019 | Convertible Notes Payable
Debt Instrument [Line Items]
Gross cash proceeds		$ 29,300,000
Senior Notes, due December 2019 | Convertible Notes Payable
Debt Instrument [Line Items]
Transaction costs											$ 300,000
Repayments of notes							13,000,000						$ 2,700,000
2023 Term Loans | Line of Credit | Term Loan
Debt Instrument [Line Items]
Number of term loans | loan					3
Initial Term Loan
Debt Instrument [Line Items]
Paid-in-kind interest option term												24 months
Increase to principal balance												$ 2,400,000			10,900,000
Initial Term Loan | Line of Credit | Term Loan
Debt Instrument [Line Items]
Face amount of the Notes					$ 50,000,000
Delayed Draw Term Loan A | Term Loan
Debt Instrument [Line Items]
Debt issuance costs												$ 500,000			$ 500,000
Proceeds from Revolver							10,000,000
Amount drawn				$ 20,000,000
Delayed Draw Term Loan A | Term Loan | Minimum
Debt Instrument [Line Items]
Interest rate, effective percentage												9.10%			9.10%
Delayed Draw Term Loan A | Term Loan | Maximum
Debt Instrument [Line Items]
Interest rate, effective percentage												12.20%			12.20%
Delayed Draw Term Loan A | Line of Credit | Term Loan
Debt Instrument [Line Items]
Face amount of the Notes					30,000,000
Delayed Draw Term Loan B | Line of Credit | Term Loan
Debt Instrument [Line Items]
Face amount of the Notes					$ 15,000,000
Debt partial extinguishment							15,000,000
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable
Debt Instrument [Line Items]
Face amount of the Notes							34,405,000					$ 34,405,000			$ 34,405,000
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable
Debt Instrument [Line Items]
Face amount of the Notes							$ 34,405,000					$ 34,405,000			$ 34,405,000
Stated interest rate		7.00%
Conversion price | $ / shares		$ 0.72					$ 0.72					$ 0.72			$ 0.72
Debt issuance costs		$ 2,300,000
Gross cash proceeds		$ 34,400,000
PIK interest		8.00%
Net proceeds from the offering		$ 26,900,000
Remeasured derivative liability							$ 6,776,000					$ 2,781,000			$ 2,781,000
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable | 2023 Series A Unsecured Convertible Notes for Series B Senior Unsecured Convertible Notes
Debt Instrument [Line Items]
Debt issuance costs												200,000			200,000
Exchanged amount		5,100,000										5,100,000
Carrying value of original debt												7,200,000			7,200,000
Fair value of embedded derivative liability												2,000,000			2,000,000
Future undiscounted cash flows												6,800,000			$ 6,800,000
Series A Unsecured Convertible Notes due 2023 | Convertible Notes Payable | 2023 Series A Unsecured Convertible Notes for Series B Senior Unsecured Convertible Notes
Debt Instrument [Line Items]
Original exchange amount		$ 9,000,000										$ 9,000,000
Senior Notes, Due 2023 [Member]
Debt Instrument [Line Items]
Interest rate at period end												27.40%			27.40%
Senior Notes, due February 2023 | Convertible Notes Payable
Debt Instrument [Line Items]
Face amount of the Notes							$ 88,464,000					$ 90,846,000			$ 90,846,000

Debt - Net Carrying Amount of L

Debt - Net Carrying Amount of Liability Component of Debt Discount (Details) - Convertible Notes Payable - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Face amount of the Notes	$ 216,341,000	$ 213,959,000
Less unamortized discounts and debt issuance costs	(25,994,000)	(27,589,000)
Total net carrying value, current	190,347,000	186,370,000
Revolving Credit Facility
Debt Instrument [Line Items]
Face amount of the Notes	25,000,000	25,000,000
Senior Notes, due May 2023
Debt Instrument [Line Items]
Face amount of the Notes	66,090,000	66,090,000
Series B Senior Unsecured Convertible Notes
Debt Instrument [Line Items]
Face amount of the Notes	34,405,000	34,405,000
Senior Notes, due February 2023
Debt Instrument [Line Items]
Face amount of the Notes	$ 90,846,000	$ 88,464,000

Derivatives - Terms and Assumpt

Derivatives - Terms and Assumptions in Valuation of Convertible Option of Notes (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)$ / shares	Oct. 31, 2019$ / shares
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability | $	$ 5,300,000
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable
Derivative Instruments, Gain (Loss) [Line Items]
Term (years)	3 years 29 days	3 years 3 months 29 days
Face amount of the Notes | $	$ 34,405,000	$ 34,405,000
Conversion price | $ / shares	$ 0.72	$ 0.72	$ 0.72
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable | Stock price
Derivative Instruments, Gain (Loss) [Line Items]
Measurement input | $ / shares	0.28	0.43
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable | Risk free rate
Derivative Instruments, Gain (Loss) [Line Items]
Measurement input	0.003	0.016
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable | Volatility
Derivative Instruments, Gain (Loss) [Line Items]
Measurement input	0.550	0.473

Derivatives - Schedule of Liabi

Derivatives - Schedule of Liabilities Measured and Recognized at Fair Value on a Recurring (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	$ 5,300
Fair Value, Recurring
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	8,034	$ 6,776
Fair Value, Recurring | Convertible Notes Payable | Series B Senior Unsecured Convertible Notes
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	2,781	6,776
Fair Value, Recurring | Revolving Credit Facility | Line of Credit
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	5,253	0
Fair Value, Recurring | (Level 1)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	0	0
Fair Value, Recurring | (Level 1) | Convertible Notes Payable | Series B Senior Unsecured Convertible Notes
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	0	0
Fair Value, Recurring | (Level 1) | Revolving Credit Facility | Line of Credit
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	0	0
Fair Value, Recurring | (Level 2)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	0	0
Fair Value, Recurring | (Level 2) | Convertible Notes Payable | Series B Senior Unsecured Convertible Notes
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	0	0
Fair Value, Recurring | (Level 2) | Revolving Credit Facility | Line of Credit
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	0	0
Fair Value, Recurring | (Level 3)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	8,034	6,776
Fair Value, Recurring | (Level 3) | Convertible Notes Payable | Series B Senior Unsecured Convertible Notes
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	2,781	6,776
Fair Value, Recurring | (Level 3) | Revolving Credit Facility | Line of Credit
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	$ 5,253	$ 0

Derivatives - Summary of Change

Derivatives - Summary of Changes in Fair Value (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Derivative Instruments and Hedging Activities, Rollforward [Roll Forward]
Balance as of 12/31/2019	$ 6,776
(Gain) or loss recognized in earnings from Change in Fair Value	1,258	$ 0
Balance as of 3/31/2020	8,034
Convertible Notes Payable | Series B Senior Unsecured Convertible Notes
Derivative Instruments and Hedging Activities, Rollforward [Roll Forward]
Balance as of 12/31/2019	6,776
(Gain) or loss recognized in earnings from Change in Fair Value	(3,995)
Balance as of 3/31/2020	2,781
Revolving Credit Facility | Line of Credit
Derivative Instruments and Hedging Activities, Rollforward [Roll Forward]
Balance as of 12/31/2019	0
(Gain) or loss recognized in earnings from Change in Fair Value	5,253
Balance as of 3/31/2020	$ 5,253

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Changes in Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2020	Jun. 30, 2019
Goodwill [Roll Forward]
Goodwill beginning balance	$ 491	$ 470
Foreign currency translation	(37)	$ 21
Goodwill ending balance	$ 454

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Major Categories of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2020	Jun. 30, 2019	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, accumulated amortization	$ (11,106)		$ (12,386)
Total	34,699		44,645
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	34,699		44,645
Intangible Assets, Net (Excluding Goodwill)	34,699		44,645
Intangible assets gross carrying amount	45,805		57,031
Intangible assets net carrying amount	34,699		44,645
Product acquisition costs
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	9,225		13,103
In process research and development ("IPR&D")
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	255		327
Trademarks and Technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	32,823		39,943
Finite-lived intangible assets, accumulated amortization	(9,516)		(10,885)
Total	$ 23,307		29,058
Weighted average remaining amortization period	10 years 6 months	10 years 9 months 18 days
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	$ 23,307		29,058
Finite-Lived Intangible Assets, Remaining Amortization Period	10 years 6 months	10 years 9 months 18 days
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	$ 3,502		3,658
Finite-lived intangible assets, accumulated amortization	(1,590)		(1,501)
Total	$ 1,912		2,157
Weighted average remaining amortization period	5 years 7 months 6 days	5 years 10 months 24 days
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	$ 1,912		$ 2,157
Finite-Lived Intangible Assets, Remaining Amortization Period	5 years 7 months 6 days	5 years 10 months 24 days

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Changes in Intangibles (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets beginning balance	$ 44,645
Amortization of intangible assets	(741)	$ (756)
Finite-lived intangible assets ending balance	34,699
Indefinite-lived Intangible Assets [Roll Forward]
Impairment charges	8,373	$ 0
Product acquisition costs
Indefinite-lived Intangible Assets [Roll Forward]
Indefinite-lived intangible assets, beginning balance	13,103
Loss on impairment	(3,512)
Foreign currency translation	(366)
Indefinite-lived intangible assets, ending balance	9,225
Impairment charges, indefinite-lived	3,512
In process research and development ("IPR&D")
Indefinite-lived Intangible Assets [Roll Forward]
Indefinite-lived intangible assets, beginning balance	327
Loss on impairment	0
Foreign currency translation	(72)
Indefinite-lived intangible assets, ending balance	255
Impairment charges, indefinite-lived	0
Trademarks and Technology
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets beginning balance	29,058
Amortization of intangible assets	(652)
Loss on impairment	(4,861)
Foreign currency translation	(238)
Finite-lived intangible assets ending balance	23,307
Indefinite-lived Intangible Assets [Roll Forward]
Impairment charges, finite-lived	4,861
Customer relationships
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets beginning balance	2,157
Amortization of intangible assets	(89)
Loss on impairment	0
Foreign currency translation	(156)
Finite-lived intangible assets ending balance	1,912
Indefinite-lived Intangible Assets [Roll Forward]
Impairment charges, finite-lived	$ 0

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Useful Lives of Intangibles (Details)	3 Months Ended
	Mar. 31, 2020
Product acquisition costs
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	10 years
Trademarks and Technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	15 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	10 years

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($)	May 25, 2016	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Stock Based Compensation Details [Line Items]
Unrecognized compensation costs		$ 1,200,000
Employee Stock Option
Stock Based Compensation Details [Line Items]
Compensation expense		$ 400,000	$ 300,000
Number of options forfeited (in shares)		66,588
Shares of common stock options outstanding (in shares)		8,081,381		5,167,739
Restricted Stock
Stock Based Compensation Details [Line Items]
Compensation expense		$ 100,000	$ 100,000
Unrecognized compensation costs		$ 36,000
Restricted Stock | Minimum
Stock Based Compensation Details [Line Items]
Vesting period		1 year
Restricted Stock | Maximum
Stock Based Compensation Details [Line Items]
Vesting period		3 years
Plan 2009
Stock Based Compensation Details [Line Items]
Additional shares authorized (in shares)	2,000,000
Number of options forfeited (in shares)	2,500,000
Plan 2016
Stock Based Compensation Details [Line Items]
Shares approved and authorized (in shares)	4,000,000
Maximum number of shares to any individual (in shares)	1,000,000
Shares of common stock options outstanding (in shares)		185,564		136,496,000
Shares available for grant (in shares)		921,089		2,334,731
Plan 2016 | Common Stock
Stock Based Compensation Details [Line Items]
Shares of common stock options outstanding (in shares)		4,278,773		2,835,131,000
Plan 2016 | Restricted Stock
Stock Based Compensation Details [Line Items]
RSUs outstanding (in shares)		13,612		62,680,000

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Valuation Assumptions (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock Based Compensation [Line Items]
Expected dividends	0.00%	0.00%
Risk-free rate		2.47%
Minimum
Stock Based Compensation [Line Items]
Risk-free rate	0.85%
Expected volatility	78.56%	57.80%
Expected term (in years)	3 years 2 months 12 days	3 years 2 months 12 days
Maximum
Stock Based Compensation [Line Items]
Risk-free rate	1.60%
Expected volatility	79.58%	60.20%
Expected term (in years)	3 years 3 months 18 days	3 years 3 months 18 days

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Stock Option Activity (Details) - Employee Stock Option	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of Options
Number of options outstanding, balance beginning (in shares) | shares	5,167,739
Number of options issued (in shares) | shares	3,049,178
Number of options exercised (in shares) | shares	0
Number of options forfeited (in shares) | shares	(66,588)
Number of options expired (in shares) | shares	(68,948)
Number of options outstanding, balance ending (in shares) | shares	8,081,381
Number of options exercisable (in shares) | shares	3,562,724
Weighted Average Exercise Price
Shares outstanding exercise price, balance beginning (in dollars per share) | $ / shares	$ 3.34
Issued, exercise price (in dollars per share) | $ / shares	0.41
Exercised, exercise price (in dollars per share) | $ / shares	0
Forfeited, exercise price (in dollars per share) | $ / shares	2.17
Expired, exercise price (in dollars per share) | $ / shares	4.81
Shares outstanding exercise price, balance ending (in dollars per share) | $ / shares	2.23
Exercisable, exercise price (in dollars per share) | $ / shares	$ 4.06

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Outstanding and Exercisable Options (Details)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options outstanding (in shares) | shares	8,081,381
Weighted average exercise price (in dollars per share)	$ 2.23
Weighted average remaining contractual life	7 years 6 months 25 days
Stock options exercisable (in shares) | shares	3,562,724
Weighted average exercise price (in dollars per share)	$ 4.06
$0.00 - $0.78
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	0
Range of exercise prices (in dollars per share)	$ 0.78
Stock options outstanding (in shares) | shares	3,228,583
Weighted average exercise price (in dollars per share)	$ 0.42
Weighted average remaining contractual life	9 years 10 months 6 days
$0.79 - $1.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	$ 0.79
Range of exercise prices (in dollars per share)	$ 1.50
Stock options outstanding (in shares) | shares	1,745,369
Weighted average exercise price (in dollars per share)	$ 1.03
Weighted average remaining contractual life	4 years 3 months 21 days
Stock options exercisable (in shares) | shares	1,370,748
Weighted average exercise price (in dollars per share)	$ 1.06
$1.51 - $5.50
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	1.51
Range of exercise prices (in dollars per share)	$ 5.50
Stock options outstanding (in shares) | shares	1,835,130
Weighted average exercise price (in dollars per share)	$ 2.30
Weighted average remaining contractual life	7 years 11 months 26 days
Stock options exercisable (in shares) | shares	934,052
Weighted average exercise price (in dollars per share)	$ 2.56
$5.51 - $10.67
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	5.51
Range of exercise prices (in dollars per share)	$ 10.67
Stock options outstanding (in shares) | shares	1,272,299
Weighted average exercise price (in dollars per share)	$ 7.69
Weighted average remaining contractual life	5 years 11 months 23 days
Stock options exercisable (in shares) | shares	1,257,924
Weighted average exercise price (in dollars per share)	$ 8.45

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary and Changes of Non-Vested Restricted Stock (Details) - Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of RSUs
Non-vested balance at beginning of period (in shares) | shares	62,680
Shares granted (in shares) | shares	0
Shares vested (in shares) | shares	(49,068)
Shares forfeited (in shares) | shares	0
Non-vested balance at end of period (in shares) | shares	13,612
Weighted Average Exercise Price
Weighted average exercise price, non-vested balance beginning (in dollars per share) | $ / shares	$ 4.07
Shares granted - weighted average exercise price (in dollars per share) | $ / shares	0
Shares vested - weighted average exercise price (in dollars per share) | $ / shares	4.36
Shares forfeited - weighted average exercise price (in dollars per share) | $ / shares	0
Weighted average exercise price, non-vested balance ending (in dollars per share) | $ / shares	$ 3.03

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income tax expense	$ 52	$ 8
Effective income tax rate reconciliation, percent	0.19%	0.09%
Operating loss carryforwards			$ 48,500

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Other Income and Expenses [Abstract]
Interest expense	$ 2,998	$ 1,539
Payroll	2,127	1,789
Professional fees	2,140	1,881
Wholesaler fees	687	747
Medicaid and Medicare rebates	863	987
Rebates	606	774
Royalties	85	377
Clinical studies	334	334
Income Tax	19	20
Capital expenditures	77	23
Inventory and Supplies	258	250
Other	200	564
Accrued expenses	$ 10,394	$ 9,285

Legal and U.S. Regulatory Pro_2

Legal and U.S. Regulatory Proceedings (Details) $ in Millions	Oct. 20, 2017USD ($)claimdrug	Mar. 31, 2020defendantlawsuit	Dec. 13, 2018drug
Anti-Trust Lawsuit
Loss Contingencies [Line Items]
Number of putative class action antitrust lawsuits | lawsuit		13
Number of defendants | defendant		47
Stayma Consulting Services
Loss Contingencies [Line Items]
Number of generic drug products	2
Number of claims under arbitration | claim	3
Stayma
Loss Contingencies [Line Items]
Damages sought | $	$ 1.7
Breach of Contract
Loss Contingencies [Line Items]
Number of generic drug products			2

Subsequent Events (Details)

Subsequent Events (Details) $ in Thousands	May 26, 2020shares	May 26, 2020USD ($)shares	May 28, 2020shares	May 04, 2020USD ($)	Mar. 31, 2020shares	Dec. 31, 2019shares
Subsequent Event [Line Items]
Common stock, shares outstanding (in shares)					53,899,495	53,850,427
Subsequent Event
Subsequent Event [Line Items]
Proceeds received under PPP | $		$ 3,300
Annual salary amount, reduction in pay | $				$ 100
Common stock, shares outstanding (in shares)	53,900,000	53,900,000
Reverse stock split, conversion ratio	0.1
Subsequent Event | Forecast
Subsequent Event [Line Items]
Common stock, shares outstanding (in shares)			5,400,000
Subsequent Event | Executive Leadership Team
Subsequent Event [Line Items]
Percentage of pay reduction				20000000.00%
Subsequent Event | All Employees
Subsequent Event [Line Items]
Percentage of pay reduction				15000000.00%